General requirements for BMP delivery systems
\r\n\tIn sum, the book presents a reflective analysis of the pedagogical hubs for a changing world, considering the most fundamental areas of the current contingencies in education.
",isbn:"978-1-83968-793-8",printIsbn:"978-1-83968-792-1",pdfIsbn:"978-1-83968-794-5",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,hash:"b01f9136149277b7e4cbc1e52bce78ec",bookSignature:"Dr. María Jose Hernandez-Serrano",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/10229.jpg",keywords:"Teacher Digital Competences, Flipped Learning, Online Resources Design, Neuroscientific Literacy (Myths), Emotions and Learning, Multisensory Stimulation, Citizen Skills, Violence Prevention, Moral Development, Universal Design for Learning, Sensitizing on Diversity, Supportive Strategies",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"September 14th 2020",dateEndSecondStepPublish:"October 12th 2020",dateEndThirdStepPublish:"December 11th 2020",dateEndFourthStepPublish:"March 1st 2021",dateEndFifthStepPublish:"April 30th 2021",remainingDaysToSecondStep:"4 months",secondStepPassed:!0,currentStepOfPublishingProcess:4,editedByType:null,kuFlag:!1,biosketch:"Dr. Phil. Maria Jose Hernandez Serrano is a tenured lecturer in the Department of Theory and History of Education at the University of Salamanca, where she currently teaches on Teacher Education. She graduated in Social Education (2000) and Psycho-Pedagogy (2003) at the University of Salamanca. Then, she obtained her European Ph.D. in Education and Training in Virtual Environments by research with the University of Manchester, UK (2009).",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"187893",title:"Dr.",name:"María Jose",middleName:null,surname:"Hernandez-Serrano",slug:"maria-jose-hernandez-serrano",fullName:"María Jose Hernandez-Serrano",profilePictureURL:"https://mts.intechopen.com/storage/users/187893/images/system/187893.jpg",biography:"DPhil Maria Jose Hernandez Serrano is a tenured Lecturer in the Department of Theory and History of Education at the University of Salamanca (Spain), where she currently teaches on Teacher Education. She graduated in Social Education (2000) and Psycho-Pedagogy (2003) at the University of Salamanca. Then, she obtained her European Ph.D. on Education and Training in Virtual Environments by research with the University of Manchester, UK (2009). She obtained a Visiting Scholar Postdoctoral Grant (of the British Academy, UK) at the Oxford Internet Institute of the University of Oxford (2011) and was granted with a postdoctoral research (in 2021) at London Birbeck University.\n \nShe is author of more than 20 research papers, and more than 35 book chapters (H Index 10). She is interested in the study of the educational process and the analysis of cognitive and affective processes in the context of neuroeducation and neurotechnologies, along with the study of social contingencies affecting the educational institutions and requiring new skills for educators.\n\nHer publications are mainly of the educational process mediated by technologies and digital competences. Currently, her new research interests are: the transdisciplinary application of the brain-based research to the educational context and virtual environments, and the neuropedagogical implications of the technologies on the development of the brain in younger students. Also, she is interested in the promotion of creative and critical uses of digital technologies, the emerging uses of social media and transmedia, and the informal learning through technologies.\n\nShe is a member of several research Networks and Scientific Committees in international journals on Educational Technologies and Educommunication, and collaborates as a reviewer in several prestigious journals (see public profile in Publons).\n\nUntil March 2010 she was in charge of the Adult University of Salamanca, by coordinating teaching activities of more than a thousand adult students. She currently is, since 2014, the Secretary of the Department of Theory and History of Education. Since 2015 she collaborates with the Council Educational Program by training teachers and families in the translation of advances from educational neuroscience.",institutionString:"University of Salamanca",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"University of Salamanca",institutionURL:null,country:{name:"Spain"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"23",title:"Social Sciences",slug:"social-sciences"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"301331",firstName:"Mia",lastName:"Vulovic",middleName:null,title:"Mrs.",imageUrl:"https://mts.intechopen.com/storage/users/301331/images/8498_n.jpg",email:"mia.v@intechopen.com",biography:"As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"6942",title:"Global Social Work",subtitle:"Cutting Edge Issues and Critical Reflections",isOpenForSubmission:!1,hash:"222c8a66edfc7a4a6537af7565bcb3de",slug:"global-social-work-cutting-edge-issues-and-critical-reflections",bookSignature:"Bala Raju Nikku",coverURL:"https://cdn.intechopen.com/books/images_new/6942.jpg",editedByType:"Edited by",editors:[{id:"263576",title:"Dr.",name:"Bala",surname:"Nikku",slug:"bala-nikku",fullName:"Bala Nikku"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"878",title:"Phytochemicals",subtitle:"A Global Perspective of Their Role in Nutrition and Health",isOpenForSubmission:!1,hash:"ec77671f63975ef2d16192897deb6835",slug:"phytochemicals-a-global-perspective-of-their-role-in-nutrition-and-health",bookSignature:"Venketeshwer Rao",coverURL:"https://cdn.intechopen.com/books/images_new/878.jpg",editedByType:"Edited by",editors:[{id:"82663",title:"Dr.",name:"Venketeshwer",surname:"Rao",slug:"venketeshwer-rao",fullName:"Venketeshwer Rao"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4816",title:"Face Recognition",subtitle:null,isOpenForSubmission:!1,hash:"146063b5359146b7718ea86bad47c8eb",slug:"face_recognition",bookSignature:"Kresimir Delac and Mislav Grgic",coverURL:"https://cdn.intechopen.com/books/images_new/4816.jpg",editedByType:"Edited by",editors:[{id:"528",title:"Dr.",name:"Kresimir",surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"44667",title:"Delivery Systems and Role of Growth Factors for Alveolar Bone Regeneration in Dentistry",doi:"10.5772/55580",slug:"delivery-systems-and-role-of-growth-factors-for-alveolar-bone-regeneration-in-dentistry",body:'Growth factors (GFs) have been investigated for the purpose of alveolar bone regeneration in periodontal, reconstructive and pre-prosthetic surgery, often with a view to rehabilitation with dental implants. Results are promising, and research is currently focusing on developing an effective delivery system capable of ensuring a controlled and localized GF release and activity. In fact, one of the main issues relating to GFs concerns how to control their effects over time so as to guarantee their effective action in the various phases of bone healing. This chapter provides a review of the literature on GFs used for bone regeneration in dentistry, emphasizing the most recent developments relating to local delivery systems.
Growth factors (GFs) are protein molecules that have a role in controlling biological processes, such as cell growth, proliferation, differentiation and repair. GFs cannot pass through a cell’s membrane; they must bind to high-affinity cell receptors in order to take effect. Many GFs stimulate several cell populations, while others are less versatile and specific to a particular cell line.
In dentistry, numerous GFs have been investigated in terms of their effect on hard and soft tissue healing and regeneration.
Whatever the tissue involved, the healing process always involves a series of molecular, biochemical and cellular events that can be grouped into three overlapping phases: inflammation, proliferation, and remodeling.
Inflammation begins spontaneously straight an after injury has occurred and lasts for 1 to 4 days. It is characterized by clotting in the wound, the release of signal molecules to recruit immune cells, and the release of specific enzymes (matrix metalloproteinases, MMPs) that clean the wound. The proliferative phase takes place between 4 and 21 days after wounding, when fibroblasts are stimulated to invade the site of the wound and produce extracellular matrix components. Highly-vascularized granulation tissue is formed and the gap is closed. The final remodeling phase can take up to a year, during which time the immature scar is converted into a stable, less vascularized tissue that exhibits good mechanical proprieties, followed by the growth of regenerated tissue.
GFs have been used in dentistry in all these phases. The most often studied GFs are probably the bone morphogenetic proteins (BMPs), discovered by Urist, who found that protein mixtures obtained from demineralized, lyophilized segments of bone were responsible for bone formation after implanting in rabbit muscle tissue [1].
BMPs are multifunctional cytokines that belong to the transforming growth factor-β (TGF-β) superfamily. They are not only involved in direct ectopic bone formation (hence their name of bone morphogenetic proteins), they also modulate several developmental processes, prompting numerous authors to suggest other names: for instance, Reddi suggested that they be should be called body morphogenetic proteins, given their extensive roles in various tissues [2].
Over 20 BMPs with various functions have been identified in humans. They have a major role in embryogenesis and in the maintenance and repair of many skeletal and non-skeletal tissues in adults [3]. BMP-1 is actually not considered a member of the BMP family, but a misnamed protein with chordinase and procollagen proteinase activities, implicated in pattern formation during the development of a number of organisms [4]. BMPs are mainly related to bone and cartilage formation, though BMPs 8b, 10 and 15 have no role in these processes, and BMPs 12, 13 and 14 are called cartilage-derived morphogenetic proteins (CDMPs) because they induce chondrogenic phenotypes rather than osteogenesis [2,5], whereas a definite bone-inducing role during bone formation has been observed for BMPs 2, 4, 6, 7 and 9 [6].
BMPs play a pivotal part in skeletal morphogenesis and repair, promoting the differentiation of mesenchymal cells into osteoblasts and inducing new bone formation. BMPs are involved in regulating mesenchymal cell differentiation and proliferation by stimulating intracellular signaling pathways. BMP signals are transmitted by the plasma membrane receptors to the nucleus through multiple signaling pathways that can be divided into two groups, the Smad and non-Smad pathways [3,7]. At the cell surface, BMP ligands bind with BMP receptors, triggering specific intracellular pathways that activate and influence gene transcription. Of the three types of receptor for the TGF-β superfamily, only types I and II appear to have significant roles in BMP binding and signaling. Five type I receptors (ALK1 [Acvrl1], ALK2 [ActRI], ALK3 [BRIa], ALK4 [ActRIb] and ALK6 [(BRIb]), and three type II receptors (BRII, ActRIIa, and ActRIIb) have been identified [8], plus a short form of BRII [9]. Type III TGF-β receptors have also been shown to have a role in BMP signaling, by mediating epithelial to mesenchymal cell conversion [10].
Canonical Smad-dependent TGF-β first binds to receptors type I and type II, and then signals are transduced to their Smads. Activated Smads form a complex with Smad4 and cross the nuclear membrane into the nucleus, where they regulate the expression of transcriptional factors and transcriptional coactivators that are important in osteoblasts (Dlx5, Runx2 and Osx). It has recently been demonstrated that, following TGF-β induction, the Smad and the p38 MAPK pathways converge on the Runx2 gene to control mesenchymal precursor cell differentiation [11].
As for the isolation of BMPs, after Urist’s experiments, BMPs were obtained from the bones of various species, including rabbit, cow and human. Nowadays, BMPs are produced and purified using DNA recombinant technology and essentially two expression systems, in mammalian cells or bacteria [6]. Recombinant human BMP-2 (rhBMP-2) and recombinant human BMP-7 (rhBMP-7) are currently the only proteins in the group to been approved by the US Food and Drug Administration (FDA) for clinical use in humans, which explains why they are clearly the most extensively evaluated BMPs [12].
Another GF of interest in dentistry is the growth and differentiation factor (GDF), the structure of which closely resembles some BMPs, so it could be included in the BMP family. GDF-5 is also known as BMP-14, or cartilage-derived morphogenetic protein 1, because it induces chondrogenic phenotypes rather than osteogenesis [6]. GDF-5 gene mutations give rise to different types of dysplasia and can result in the autosomal recessive syndromes of brachypod in mice and Hunter-Thompson or Grebe-type chondrodysplasia in humans, involving a loss of joints in both humans and mice [13-15]. Francis-West and colleagues [14] showed that GDF-5 can modulate the initial stages of chondrogenesis by increasing cell adhesion, and can increase chondrocyte proliferation in the later stages of skeletogenesis.
The osteoinductive potential of GDF-5 has been found smaller than that of other members of the BMP family, though numerous studies have confirmed its crucial role in skeletal morphogenesis. Several in vitro experiments have demonstrated that rhGDF-5 stimulates osteogenic differentiation and promotes angiogenic activity by increasing vascular endothelial growth factor gene expression in fat- or bone-marrow-derived stromal cells. The osteoinductive activity of rhGDF-5 has also been examined in numerous in vivo model systems [13].
Another GF extensively investigated for clinical applications is the platelet-derived growth factor (PDGF), which is synthesized by platelets, monocytes, macrophages, endothelial cells and osteoblasts. This is a dimeric molecule consisting of disulfide-bonded, structurally similar A- and B-polypeptide chains that combine to form homo- and heterodimers. The biologically most potent of these PDGFs is PDGF-BB, which has been thoroughly investigated. The PDGF isoforms exert their cellular effects by binding to and activating two structurally related protein tyrosine kinase receptors, called the alpha-receptor and the beta-receptor [16,17].
PDGF is stored in the alpha granules of circulating platelets and is released during blood clotting in the event of soft or hard tissue injury. Once it has been released from the platelets, PDGF binds to specific cell surface receptors and promotes rapid cell migration (chemotaxis) and proliferation (mitogenesis) at the site of injury. In particular, in vitro and in vivo studies have demonstrated that PDGF is a potent chemotactic and mitogenic factor for gingival and periodontal ligament fibroblasts, cementoblasts and osteoblasts [18].
Since the first animal study conducted by Lynch and co-workers [19], extensive in vitro, preclinical and clinical studies have been performed using PDGF, alone or in combination with other GFs, for incrementing bone vertically and horizontally, and for treating periodontal and peri-implant defects. The positive outcomes of these studies provide strong evidence of the safety and predictably of rhPDGF combined with specific scaffolds in periodontal and peri-implant regeneration, suggesting promising clinical applications [18,20,21].
Although a large body of preclinical and clinical data has been obtained for only a few GFs, others have nonetheless been assessed for possible applications in clinical practice.
The activity and osteoinductive potential of fibroblast growth factor (FGF) have been the object of various studies [22-24]. FGF signaling reportedly interacts with BMP signaling in bone formation, showing a synergic action on osteogenesis [11].
Few studies have considered the use of parathyroid hormone (PTH) as a factor for modulating bone augmentation and healing [25]. PTH binding activates PTH1R to stimulate several downstream effectors and also drives the internalization of the PTH1R(PTH type I receptor)-TGFβRII (TGF-β type II receptor) complex, which attenuates both TGF-β and PTH signaling on bone development. The transcriptional factor/cAMP response element binding protein (CREB) mediates PTH signaling in osteoblasts, and the PTH-CREB signaling pathway serves as an effective activator of BMP-2 expression [11].
Transforming growth factor-β (TGF-β) [26-27], vascular endothelial growth factor (VEGF) [24], and insulin-like growth factor (IGF) [28] are also the object of studies regarding the biological properties of these bioactive molecules.
Given the biological properties of GFs, a major focus of research has concerned the clinical application of the osteoinductive proteins, such as some BMPs, for enhancing new bone formation. Bone loss involving the teeth may be secondary to diseases such as periodontitis, cystic diseases or tumors, or the consequence of trauma. Alveolar bone augmentation procedures are often needed for the purpose of inserting dental implants for prosthetic rehabilitation.
Missing teeth can be replaced with prostheses supported on dental implants, which can only be inserted in patients with an adequate alveolar ridge height and/or thickness, so bone augmentation procedures enable implant treatments in cases in which it would otherwise not be an option. Bone augmentation procedures can be performed prior to implant placement (in a two-stage procedure), or during the same surgical procedure (one-stage procedure), using numerous materials and techniques.
Various options have been described [29], including: autogenous bone grafts, allografts, xenografts, alloplastic grafts, barrier membranes for guided bone regeneration (GBR), growth factors (and BMPs in particular), platelet-rich plasma (PRP), inlay grafting, onlay grafting, ridge expansion, and distraction osteogenesis.
Tonetti et al. [30] described various techniques that have been developed to correct inadequate vertical and horizontal bone volumes, such as guided bone regeneration (GBR), sinus lift and onlay bone grafting.
Bone augmentation techniques have also been promoted as a means for treating periodontal and peri-implant diseases in an effort to regenerate lost periodontal or peri-implant soft and hard tissues [31-32].
Autogenous bone grafts are still considered the gold standard for bone repair in most cases, though there are some restrictions in their use in clinical practice because of the morbidity of the harvesting procedures and the limited amount of bone available. Many authors have consequently been studying the biocompatibility and effectiveness of other materials as potential substitutes for autogenous bone grafts.
The most recent and promising approach consists in applying osteoinductive growth factors to promote new bone formation (protein therapy) [33], providing a new alternative to autogenous grafts and other bone substitutes.
Combining growth factors with osteoinductive scaffolds may facilitate a faster and more significant enhancement of new bone formation thanks to the delivery of the growth factors at the site of the graft, and because their three-dimensional stability provides protection during the gradual replacement of the graft with newly-formed bone. Numerous materials have been used in combination with GFs, including inorganic bovine bone, porous hydroxyapatite and demineralized human bone matrix.
Numerous pre-clinical and clinical studies have looked into how GF implantation influences bone augmentation and implant osteointegration, focusing particularly on recombinant human BMP-2 (rhBMP-2), rhBMP-7 and recombinant human growth and differentiation factor-5 (rhGDF-5), combined with a variety of biomaterials used as scaffolds and delivery systems.
Although the potential value of GFs in alveolar bone regeneration and augmentation has been highlighted by numerous authors [6,31,34-35], it is still difficult to assess the different biological potential of each growth factor, because few analyses have compared different growth factors under identical in vivo conditions [24].
There is still much to learn about osteogenic growth factors: only a handful of growth and differentiation factors have been the object of clinical evaluation [6,18,25] and further studies are needed to identify predictable clinical outcomes.
Several surgical techniques and materials - including the use of GFs - have been introduced with a view to increasing bone volume in order to enable the placement of dental implants.
The systematic literature review conducted by Jung and coworkers [25] assessed the clinical, histological and radiographic outcomes after BMP-2, BMP-7, GDF-5, PDGF, and PTH had been used for localized alveolar ridge augmentation. Altogether, 74 studies met the authors’ inclusion criteria, including 6 on the outcome of BMP-2 for localized alveolar ridge augmentation in humans; the remainder were pre-clinical studies involving BMP-2, BMP-7, GDF-5, PDGF, and PTH. For all the GFs other than BMP-2, no human studies met the inclusion criteria. Concerning the animal studies, most of those on BMP-2 (43 out of 45) showed a positive effect of this growth factor. Six of 8 studies reported a positive effect of BMP-7. The one animal study on GDF-5 spoke of a statistically significant increase in bone volume. Five of 10 studies involving the use of PDGF also reported a statistically significant increase in bone volume. Four animal studies identified a significantly greater bone regeneration in cases treated with PTH than in controls. In the six human studies, BMP-2 influenced local bone augmentation, with a dose-dependent increase in bone volume. The dose of BMP-2 delivered seemed to have an impact on treatment outcome, local bone regeneration being greater for higher BMP-2 doses [36-38], with a smaller decrease in bone height at extraction socket sites [39]. Four of these six human studies were designed as randomized-controlled clinical trials (RCT) [37-40], the other two as prospective cohort studies [36,41]. The locally-applied dose of BMP-2 ranged from 0.5 to 1.75 mg/ml, or 0.12 to 3.4 mg/patient, respectively. An absorbable collagen sponge (ACS) was used in five studies, while Jung et al. [40] used a demineralized bovine bone matrix (DBBM) as a carrier. The treatments included sinus floor augmentation [38,41], extraction socket preservation [36-37,39], augmentation of localized ridge defects [36], and lateral ridge augmentation combined with simultaneous implant placement [40].
The 16-week open-label study conducted by Boyne and coworkers [41] assessed the safety and efficacy of implanting BMP-2 delivered on an absorbable collagen sponge (rhBMP-2/ACS) for two-stage maxillary floor sinus augmentation. The dose of rhBMP-2 ranged from 1.77 to 3.40 mg per patient. Significant bone growth was documented by computed tomographic (CT) scans in all evaluable patients (11/12), with an overall mean response of 8.51 mm in height (±4.13 mm). Histology on core bone biopsies obtained when the dental implant was inserted confirmed the good quality of the bone induced by rhBMP-2/ACS.
In a more recent RCT, Boyne and colleagues [38] found no statistically significant differences in terms of the increase in ridge height, as measured using CT scans, between their treatment and control (bone graft) groups, and even a narrower ridge width in the former after using BMP-2/ACS in two-stage maxillary floor sinus augmentations.
Bianchi et al. [37] investigated the efficacy of different concentrations of rhBMP-2 in regenerating bone in alveolar defects in the anterior maxilla, reporting a positive outcome in terms of bone volume augmentation.
Another RCT [39] compared the efficacy of rhBMP-2 in two different concentrations, delivered on ACS, with placebo ACS alone in 80 patients requiring local alveolar ridge augmentation for buccal wall defects (> or =50% buccal bone loss around the extraction socket) immediately after tooth extraction of the maxillary bicuspids. They found no statistically significant effects of BMP-2 on the treatment outcome when a lower dose was used, but a statistically significant positive effect of a higher dose (1.50 mg/ml rhBMP-2/ACS). In addition, bone density and histology revealed no differences between newly-induced and native bone.
Finally, Jung et al. [40] tested whether adding rhBMP-2 to a xenogenic bone substitute mineral could improve guided bone regeneration in the case of bone defects requiring lateral bone augmentation procedures and simultaneous implant placement. Following implant insertion (baseline), the peri-implant bone defect height was measured from the implant shoulder to the first implant-bone contact. The authors reported a positive, but statistically insignificant effect of BMP-2 on the amount of newly-formed bone (37±11.2%) compared with the control group (30± 8.9%). On the other hand, they found more mature lamellar bone (76±14.4% versus 56±18.3%) and a greater area of bone-to-graft contact (57±16.2% versus 30±22.6%) at the BMP-2-treated sites.
Various methods have been described for increasing bone volume before or at the time of positioning implants [25], one of the best-documented of these methods being GBR for intra-oral bone augmentation. To overcome some of the drawbacks of this technique, e.g. a long treatment time, the difficulty of predicting any vertical bone augmentation, the risk of infection after membrane exposure, research has concentrated on the use of bioactive molecules that induce local bone formation. Using the GBR technique, the width and height of the alveolar ridge is increased in areas of insufficient bone volume by applying barrier membranes, alone or in combination with bone grafts or substitutes.
Misch [42] published a human case series of atrophic posterior mandible augmentation prior to implant insertion, using recombinant human BMP-2 2/absorbable collagen sponge (rhBMP-2/ACS) and titanium mesh. All the 10 implants involved in the study, inserted after a 6-month healing period, became integrated and were restored with single crowns.
Many in vivo studies used critical-size supra-alveolar peri-implant defect models and other bone augmentation methods simultaneously with implant insertion. In an animal study, Sigurdsson et al. [43] found that defect sites implanted with rhBMP-2⁄ACS showed signs of a statistically significant and clinically relevant vertical alveolar bone augmentation by comparison with controls (ACS). Although the titanium implant was osseointegrated after a 16-week healing interval, the BIC (bone-to-implant contact) was lower than in resident bone, as was to be expected; the newly-induced bone was often in a thin layer on the implant surface, probably due to the unpredictability of ACS in providing adequate space for new bone formation.
Wikesjö and colleagues [44] subsequently used a critical-size supra-alveolar peri-implant defect model to study the efficacy of an ePTFE GBR device in supporting rhBMP-2⁄-induced bone formation in dogs. The space-providing macro-porous membrane was characterized by the ability to prevent the compression of the rhBMP-2/ACS construct, while allowing for vascularization via the gingival connective tissue. The authors compared GBR alone with rhBMP-2(0.4 mg)⁄ACS and rhBMP-2(0.4 mg)⁄ACS combined with GBR. Histometric analysis on block biopsies after an 8-week healing interval revealed the best results in the third sample, i.e. the GBR-rhBMP-2⁄ACS combination, which revealed bone formation filling the dome-shaped GBR device, with a vertical bone gain at the turned implants averaging 4.7 ± 0.2 mm, and an induced bone area of 9.6 ± 0.7 mm2, generating a highly-significant correlation between the induced bone area and the space provided by the GBR device. This study highlighted the crucial importance of providing space in order to obtain clinically significant benefits from a BMP construct.
Jung et al. [45] ran a randomized-controlled clinical trial with a split-mouth design, in which implants were placed in sites exhibiting lateral bone defects and patients were randomly selected for treatment with demineralized bovine bone mineral and bioresorbable collagen membrane, with (test) or without (control) the addition of rhBMP-2. After an average healing period of 6 months, a reentry operation was performed for abutment connection and prosthetic reconstruction. At the 3-year follow-up, all 34 implants in all 11 patients were clinically stable and radiologically osseointegrated. At the 5-year follow-up, 32 implants were stable and functioning, while 2 were not re-examined because the patient had moved away. The survival rate of the implants examined at 3 and 5 years was therefore 100% for both the test and the control sites. The periapical radiographs of the test and control sites also showed no peri-implant radiolucency at the 3- and 5-year follow-up examination, demonstrating healthy peri-implant tissues with minimal marginal bone loss, and only minor prosthetic complications were recorded. In short, both the test and the control sites revealed excellent clinical and radiological outcomes after 3 and 5 years, with no statistically significant differences in any of the parameters examined (though the authors emphasized the need for a larger group of patients in future studies).
In a micro-CT study in dogs, Al-Hazmi and co-workers [20] assessed the efficacy of using PDGF-BB and xenografts, with or without collagen membranes, for GBR around immediate implants with buccal dehiscence defects. They concluded that using PDGF and xenografts resulted in greater BBT (buccal bone thickness), BBV (buccal bone volume), VBH (vertical bone height) and BIC (bone-to-implant contact) when used alone rather than in combination with a collagen membrane. Their results are consistent with the report from Simion et al. [46], who said that barrier membranes may interfere with the chemotactic effect of GFs on periosteal pluripotential mesenchymal cells.
Further studies are nonetheless warranted to investigate the influence of barrier membranes on the periosteal pluripotential mesenchymal cells [20].
Most of the clinical studies on rhPDGF have focused on periodontal and peri-implant regeneration, and only a few human studies have investigated ridge preservation for implant placement in extraction socket defects [47], or three-dimensional ridge augmentation [48].
In a pilot study, Nevins et al. [47] tested whether mineralized collagen bone substitute (MCBS) combined with recombinant human platelet-derived growth factor-BB (0.3 mg/mL) could generate enough viable bone in buccal wall extraction defects to enable implant placement.
In a more recent clinical study, Nevins and colleagues [49] focused on human buccal plate extraction socket regeneration with recombinant human platelet-derived growth factor BB or enamel matrix derivative. Buccal plate resorption is a critical issue when it comes to implant placement. They compared four groups: A (mineral collagen bone substitute [MCBS] scaffold alone), B (MCBS with recombinant human platelet-derived growth factor BB [rhPDGF-BB; 0.3 mg/mL]), C (MCBS with enamel matrix derivative [EMD]), and D (a combination of EMD with bone ceramic). Grafting was done at the time of extraction, advancing the buccal flap for primary closure. Histology on trephine core biopsies of the implant site performed 5 months later, at the time of implant placement, identified new bone healing around the biomaterial scaffolds with no statistically significant differences between the four treatment groups. There was a histomorphometric trend towards a greater quantity of new bone in the rhPDGF-BB-treated group, with the most favorable ridge morphology for the purposes of an optimal implant placement at reentry surgery.
Simion et al. [48] reported on two human cases of patients who underwent three-dimensional ridge augmentation using a xenograft combined with rhPDGF-BB. In the first patient, a deproteinized bovine block infused with rh-PDGF was attached to the alveolar crest with two screws to obtain a horizontal ridge augmentation. The second patient underwent a vertical ridge augmentation procedure involving deproteinized bovine bone particles embedded in a collagen matrix soaked in rhPDGF-BB. Three titanium dental implants were placed in each patient 5 months later with excellent clinical and histological outcomes, mean that rhPDGF-BB in combination with a deproteinized bovine graft has promise in applications for regenerating large three-dimensional alveolar defects in humans.
Another interesting approach to enhancing alveolar ridge augmentation with a view to dental implant placement involves using implants coated with GFs.
Wikesjo and colleagues [35] reviewed the literature on implants coated with a bone-inductive factor capable of stimulating local bone formation and osseointegration. They concluded that rhBMP-2 can be delivered successfully for the purposes of inducing local bone formation and osseointegration by using screw-type endosseous oral implants with titanium oxide surfaces with open pores as a carrier. They also found that purpose-designed implant surfaces coated with rhBMP-2 resulted in the formation of Type II bone and significant osseointegration without any need for biomaterials or devices for GBR.
In an in vivo animal model, Susin et al. [50] used the critical-size supra-alveolar peri-implant defect model to assess the potential of a purpose-designed porous titanium oxide implant surface coated with rhBMP-7 for inducing alveolar bone formation and enhancing osseointegration. The animals received implants coated with rhBMP-7 at 1.5 or 3.0 mg/ml randomized to the contralateral jaw quadrants. The authors found clinically relevant bone formation and osseointegration with no statistically significant differences in terms of bone formation between the sites treated with rhBMP-7 at 1.5 or 3.0 mg/ml. Histology showed an increase in the height and area of the bone, and the newly-formed bone exhibited the same characteristics as the contiguous resident bone. Their observations support the significant clinical value of rhBMP-7 in inducing bone regeneration, but the authors made the point that higher concentrations were associated with some local side effects.
Other authors [e.g. 51-52] have investigated in vivo the potential of an rhGDF-5 coating on an oral implant with a porous titanium oxide surface for stimulating local bone formation, including osseointegration and vertical augmentation of the alveolar ridge.
Polimeni and co-workers [51] examined a bilateral critical-size, 5 mm, supra-alveolar peri-implant defect model in dogs. Six animals received implants coated with 30 or 60 µg rhGDF-5, and another six animals received implants coated with 120 µg rhGDF-5 or left uncoated (controls). The implants coated with rhGDF-5 displayed only limited peri-implant bone remodeling in the resident bone, as measured using fluorescent bone markers, with the 120 µg dose coinciding with a more advanced remodeling than the 60 and 30 µg doses. These results suggest a dose-dependent osteoinductive and/or osteoconductive effect of rhGDF-5-coated oral implants. Leknes et al. [52] performed an in vivo study in dogs that consisted in placing different kinds of implant in the alveolar ridge of the posterior mandible following the surgical extraction of the premolars and reduction of the alveolar ridge. Six animals were treated with implants coated with rhGDF-5 in doses of 30 or 60 μg/implant in contralateral jaw quadrants, while six received implants coated with rhGDF-5 at 120 μg/implant or uncoated implants (for control purposes), using a split-mouth design. The radiographs showed a dose-dependent formation of mineralized tissue significantly greater than around the uncoated implants, the greatest increase corresponding to the implants coated with 60 μg and 120 μg of rhGDF-5, and amounting to approximately 2.2 mm in both cases at 8 weeks. The authors also reported no adverse events, such as peri-implant bone remodeling, implant displacement, or seroma formation.
The above-mentioned studies indicate that these GFs have great potential for stimulating clinically relevant local bone formation, though it should be emphasized that further studies are essential to address their most appropriate dosage, carriers, and applications, as well as the long-term prognosis of GF-coated titanium implants.
Sinus floor elevation with immediate or delayed dental implant placement is a well-known technique for dental rehabilitation in cases of severe atrophy of the posterior maxilla due to the extension and pneumatization of the maxillary sinus. Many materials, such as autografts, xenografts, and synthetic bone substitutes, have been shown to achieve acceptable clinical results when used in maxillary sinus floor augmentations [53]. The use of GFs with various carriers and dosages has recently been investigated in combination with sinus augmentation procedures too.
Ho and colleagues [54] assessed the efficacy of various bioimplants used in maxillary sinus lift procedures with the lateral window approach in a rabbit model. They compared particulated autogenous bone, demineralized bone matrix (DBM), DBM combined with purified BMP-7 (BMP-7/DBM bioimplants), and bioimplants consisting of a poloxamer gel with BMP-7 in two different doses. In their animal model, BMP-containing bioimplants had produced more new bone and a greater new bone surface area at 2 weeks than autografts, but the advantage of these bioimplants subsequently seemed to be lost, since the differences between the bioimplants and the autografts had disappeared by 8 weeks. The authors concluded that BMP-containing bioimplants prompt a more rapid bone formation, possibly offering a greater implant stability earlier in the healing period, and therefore enabling clinicians to place osseointegrated implants in augmented maxillae sooner after grafting.
In a clinical study, Boyne and colleagues [38] compared different concentrations of rhBMP-2 (0.75 and 1.5 mg/mL), delivered on an absorbable collagen sponge (ACS) carrier, with bone grafts to identify a safe and effective concentration of rhBMP-2 for use in maxillary sinus floor augmentation procedures. Judging from density measurements on CT scans obtained before and 4 months after treatment, and 6 months after functional loading of the dental implants, and from core biopsies obtained at the time of placing the dental implant, they established that the 1.5 mg/mL dose of rhBMP-2/ACS was more appropriate in a pivotal, randomized, multicenter study to compare rhBMP-2/ACS with conventional bone graft for staged maxillary sinus floor augmentation to support dental implants for long-term functional loading.
These data prompted a randomized, parallel evaluation of rhBMP-2/ACS and autogenous bone grafts for two-stage maxillary sinus floor procedures [55]: 160 individuals with less than 6 mm of native bone height in the posterior maxilla were randomized for treatment with 1.5 mg/mL rhBMP-2/ACS or an autograft. Height and density measurements were obtained on CT scans, and core biopsies obtained at the time of dental implant placement underwent histological examination. A significant amount of new bone had formed by 6 months postoperatively in both treatment groups, but there was a significant difference in the density of the newly-induced bone at the 6-month follow-up, which was denser in the bone graft group than in the group treated with rhBMP-2/ACS. Six months after dental restoration (functional loading), however, the bone induced in the rhBMP-2/ACS group was significantly denser than in the bone graft group. No major differences emerged between the two groups in terms of the histological parameters. 17% of the patients in the autograft group experienced long-term parasthesia, pain, or gait disturbance relating to the bone graft harvest. Adverse reactions frequently recorded in the rhBMP-2/ACS group related to excessive facial swelling, and this edema was attributed to the chemotactic cellular recruitment to the site of rhBMP-2 implantation and neovascularization of the grafted area; although it was severe, this edema did not adversely affect the outcome. This study confirmed the efficacy and safety of rhBMP-2/ACS by comparison with bone grafting for sinus floor augmentation, given the morbidity, cost, and increased surgical time associated with the harvesting of autogenous bone.
Kao and coworkers [56] measured the bone formation after a lateral window sinus augmentation with recombinant human BMP-2/ absorbable collagen sponge (rhBMP-2/ACS) in combination with Bio-Oss by comparison with the results achieved with a Bio-Oss graft alone. Histology demonstrated that less new bone formed in patients treated with rhBMP-2/ACS + Bio-Oss than in those treated with Bio-Oss alone, pointing to a negative effect on bone formation of combining rhBMP-2 with Bio-Oss for maxillary sinus augmentation.
Gruber and coworkers [57] studied a GF closely related to the BMP family - the recombinant human growth and differentiation factor-5 (rhGDF-5) - in an in vivo study involving the use of different materials in sinus floor augmentation procedures in Goettingen miniature pigs. They demonstrated that associating rhGDF-5 with β-tricalcium phosphate (β-TCP) enhanced bone formation by comparison with the results obtained using the β-TCP carrier material alone.
In a further study using a split-mouth study design, the same authors [13] compared rhGDF-5-coated β-TCP with particulated autogenous bone grafts combined with the scaffold material (β-TCP). In each minipig, the sinus floors were augmented (simultaneously inserting the dental implants) with β-TCP mixed with autogenous cortical bone chips on one side, and using β-TCP coated with two different concentrations of rhGDF-5 on the contralateral side. Histology and histomorphometric analyses demonstrated that rhGDF-5-coated β-TCP not only enhanced new bone formation, but also - by comparison with a combination of β-TCP and autogenous bone chips - induced a significant increase in VD (volume density) and BIC (bone-to-implant contact) in the augmentation material.
Stavropoulos et al. [58] ran a prospective, multicenter, randomized clinical trial to examine the histological outcome of maxillary sinus lifting with rhGDF-5/β-TCP or β-TCP and autogenous bone (β-TCP/AB) composite. Thirty-one patients requiring unilateral maxillary sinus floor augmentation with a residual alveolar bone height <5 mm were treated using a lateral window approach. Cylindrical biopsies were harvested with a trephine bur during implant site preparation 3 or 4 months after sinus floor augmentation (three groups (a) rhGDF-5/b-TCP and a 3-month healing period, (b) rhGDF-5/b-TCP and a 4- month healing period, and (c) b-TCP/AB and a 4-month healing period). Histological and histometric analyses showed that sinus augmentation with rhGDF-5/β-TCP resulted in new bone in comparable amounts and of similar quality to the bone obtained with a β-TCP/AB composite graft, suggesting that rhGDF-5/β-TCP could eliminate the need for AB grafting in sinus lift procedures.
Though these favorable regenerative findings are encouraging, further studies are needed to ascertain the influence of GFs on the amount and quality of new bone formation, and on the implant survival rate after sinus lift procedures.
Periodontitis is a widely prevalent inflammatory disease of the tissues supporting the teeth, characterized by a progressive loss of bone and attachment.
The ultimate goal of periodontal therapy is the regeneration of periodontal tissues, which consists in stimulating new cementum formation, new alveolar bone apposition, and a functionally-oriented periodontal ligament reconstruction. Various techniques have been suggested for promoting periodontal tissue regeneration, using different bone graft materials that have gained clinical acceptance in the treatment of periodontal defects.
To overcome the weaknesses of conventional regenerative procedures, the predictability of which may be limited to selected case types, using GFs with biocompatible scaffolds to promote tissue regeneration may represent a new and promising periodontological approach.
After preliminary in vitro experiments, extensive in vivo preclinical studies have been performed to assess the potential and safety of using various GFs, alone or in combination, to treat periodontal defects.
A recent animal study by Oortgiesen et al. [23] investigated the regenerative potential of an injectable macroporous calcium phosphate cement (CaP) combined with BMP-2 or fibroblast growth factor-2 (FGF-2) in intrabony defects. After 12 weeks, only the CaP revealed limited effects on both periodontal ligament (PDL) and bone healing, while a good response in terms of bone healing was also seen with CaP/BMP-2 and CaP/FGF-2. The best PDL healing scores coincided with the combined CaP/FGF-2 treatment, suggesting that associating a topical application of FGF-2 with an injectable CaP might be a promising treatment for the purposes of periodontal regeneration.
Ishii and colleagues [22] investigated the effect of the combined use of basic FGF-2 and beta tricalcium phosphate (β-TCP) on root coverage in a dog model, finding that FGF-2/β-TCP enhanced the formation of new bone and cementum without any significant root resorption.
Kitamura et al. [59] undertook a multi-center, randomized, double-blind, placebo-controlled, dose-finding study on the potential of local applications of FGF-2 in periodontal regeneration. Modified Widman periodontal surgery was performed, during which 200 μL of the investigational formulation containing 0% (vehicle alone), 0.2%, 0.3%, or 0.4% FGF-2 was administered to 2- or 3-walled vertical bone defects in 253 adult patients with periodontitis. The primary outcome was the percentage of bone fill visible on radiographs 36 weeks after administering the treatment. All the doses of FGF-2 were significantly superior to the vehicle alone (p < 0.01) in terms of the percentage of bone fill, and this percentage peaked in the 0.3% FGF-2 group. No significant differences were observed between the four groups in terms of the regained clinical attachment (CAL), with all patients scoring around 2 mm (this was judged to be due to the different healing patterns between the FGF-2 groups and the ‘vehicle alone’ group). Conventional periodontal surgery (which corresponds to the ‘vehicle alone’ group) usually gives rise to long junctional epithelial attachments, but manual probing cannot precisely distinguish fibrous from epithelial attachments, so the difference in healing pattern cannot be reflected in the CAL regained by the different treatment groups. This limitation could have been overcome by histology, but this was not done for ethical reasons. No clinical safety issues emerged in this study. These results support the efficacy and safety of topical FGF-2 applications for periodontal regeneration in humans.
When implanted in furcation defects exposed surgically or by inflammatory processes in Papio ursinus, recombinant human osteogenic protein-1 (hOP-1) or BMP-7 tends to induce cementogenesis with the insertion of de novo generated Sharpey’s fibers. Long-term studies on P. ursinus after hOP-1 implantation show a highly-organized periodontal ligament space with periodontal ligament fibers cursing from the newly-formed and mineralized cementum to the regenerated alveolar bone, with a multitude of supporting capillaries throughout the periodontal ligament space [60].
In an experimental study by Teare et al. [27], binary applications of hOP-1 and hTGF-β(3) were implanted in Class II furcation defects of the mandibular molars of Chacma baboons (P. ursinus) to induce periodontal tissue regeneration. Sixty days after implantation, the animals were killed and histological and histomorphometric studies led the authors to conclude that hOP-1 and hTGF-β(3) in Matrigel(®) matrix induced substantial periodontal tissue regeneration and cementogenesis.
In their review, Ripamonti et al. [61] emphasized the induction of bone formation by the osteogenic proteins of the TGF-beta superfamily in the nonhuman primate, P. ursinus.
In a recent study in beagle dogs, Kim and co-workers [62] compared a candidate β-tricalcium phosphate (β-TCP) carrier technology with the absorbable collagen sponge (ACS) benchmark for supporting rhGDF-5-stimulated periodontal wound healing/regeneration in intrabony periodontal defects. Both solutions stimulated the formation of functionally-oriented periodontal ligament, cellular mixed-fiber cementum, and woven/lamellar bone, but bone regeneration (height and area) was significantly greater for the rhGDF-5/β-TCP construct. The structural integrity of the β-TCP carrier preventing compression while providing a framework for bone ingrowth may account for these results.
A phase IIa randomized controlled clinical and histological pilot study was conducted to assess rhGDF-5/β-TCP for periodontal regeneration [63]. Twenty chronic periodontitis patients participated in the study, each with at least one tooth scheduled for extraction with a probing depth (PD) ≥6 mm and an associated intrabony defect ≥4 mm following basic periodontal therapy. Participants (one defect/patient) were randomized to receive open flap debridement (OFD) + rhGDF-5/β-TCP (n = 10) or OFD alone (control; n = 10). Both protocols resulted in statistically significant clinical improvements. Descriptive statistics showed a greater reduction in PD after OFD with rhGDF-5/β-TCP than after OFD alone (3.7 ± 1.2 versus 3.1 ± 1.8 mm; p = 0.26), as well as less gingival recession (0.5 ± 0.8 versus 1.4 ± 1.0 mm; p < 0.05) and a greater CAL gain (3.2 ± 1.7 versus 1.7 ± 2.2 mm; p = 0.14) at the deepest aspect of the defect. Block biopsies of the defect sites were collected 6 months after surgery and prepared for histology. Five biopsies (1 rhGDF-5/β-TCP; 4 OFD) were deemed unsuitable for histological or histometric evaluation. Bone regeneration height (2.19 ± 1.59 versus 0.81 ± 1.02 mm; p = 0.08) and PDL (2.16 ± 1.43 versus 1.23 ± 1.07 mm; p = 0.26), cementum (2.16 ± 1.43 versus 1.23 ± 1.07 mm; p = 0.26) and bone regeneration area (0.74 ± 0.69 versus 0.32 ± 0.47 mm2; p = 0.14) were greater at sites treated with rhGDF-5/β-TCP compared to controls. These differences failed to reach statistical significance, however, and the authors said that further studies on larger samples will be needed to verify these findings.
The potential of PDGFs for promoting new bone formation and/or periodontal wound healing/regeneration has been examined in a variety of pre-clinical animal models. In vivo experimental studies have been performed using PDGF-BB alone or in combination with other GFs, such as insulin-like growth factor (IGF), and shown that these growth factors promoted new bone, cementum and periodontal ligament formation in vivo.
The first human clinical trial testing the effect of rhPDGF/rhIGF-I in periodontal defects was reported by Howell and colleagues [64] with promising results.
Early human clinical studies used rhPDGF-BB combined with bone allografts. An alternative is to use a synthetic system, such as β-tricalcium phosphate (β-TCP). Since rhPDGF applications have proved clinically effective in the treatment of intrabony defects, this growth factor has also been considered for the treatment of soft tissue recession defects [18].
Jayakumar and coworkers [65] ran a double-blind, prospective, parallel, active-controlled, randomized, multi-center clinical trial on the efficacy and safety of rhPDGF-BB with β-TCP in human intraosseous periodontal defects. Fifty-four patients with periodontal osseous defects were randomly grouped for treatment with rhPDGF-BB/β-TCP or β-TCP alone. A total number of 50 defects in 25 patients in the rhPDGF-BB/β-TCP group and 25 in the β-TCP group were ultimately available for statistical analysis. The radiographic parameters considered were linear bone growth (LBG) 6 months after surgery and percent bone fill (% BF), both of which were found significantly higher in the rhPDGF-BB/β-TCP group than in the β-TCP group. There also emerged a significantly higher area under the curve for clinical attachment level gain from 0 to 6 months, and a greater reduction in PD at the third and sixth month than after β-TCP treatment alone. The implantation of rhPDGF-BB/β-TCP for the treatment of intraosseous periodontal defects was safe and well tolerated, and resulted in clinically and statistically significant improvements in bone formation parameters and soft tissue outcomes.
Preliminary investigations thus indicate that GFs have great potential for improving periodontal regeneration, but randomized clinical trials must be conducted to gain a better understanding of the role of GFs in periodontal treatments, focusing particularly on establishing the safety and efficacy of their application.
The great potential of GFs in bone regeneration has been discussed by numerous authors [6,31,34-35]. BMP-2 and BMP-7 have a marked effect on bone and cartilage growth and the maintenance of homeostasis during bone remodeling [66]. One of their limitations, on the other hand, seems to be the unpredictable nature of the resulting tissue regeneration in vivo. It has been suggested that the clinical efficacy of recombinant human forms of BMPs (rh-BMPs) depends on the carrier system used to ensure an effective delivery of adequate protein concentrations to the site being treated [67]. BMPs are soluble proteins and, delivered in a buffer solution, they undergo rapid degradation, leading to an insufficient bioavailability. Other factors, such as protein competition, enzymatic activity, temperature, pH and salt concentration, may also influence the total amount of active protein available immediately after its administration [68].
In 2007 Giannoudis et al. [69] came up with the “Diamond Concept” to describe the conditions needed for osteogeneration, i.e. mechanical stability at the site of the defect, and osteogenic cells combined with osteoinductive growth factors and a suitable carrier or delivery system.
The main purpose of the delivery system is to ensure adequate protein concentrations at the defect site for as long as it takes to enable the regenerative cells to migrate, proliferate and differentiate [33].
A localized, controlled release is also necessary to prevent any unwanted and uncontrolled ectopic bone formation in non-bony body tissues [70]. Supra-physiological concentrations resulting from imperfect GF release kinetics have been correlated with severe clinical complications, including generalized hematomas in soft tissues and peri-implant bone resorption. Other potential concerns theoretically include carcinogenicity and teratogenic effects [70].
Few authors have investigated the influence of GF release kinetics on bone regeneration. In physiological bone repair, some growth factors (such as BMP-2) are expressed mainly during the early inflammatory phase. Others are up-regulated during the chondrogenic and osteogenic phases, and have a biphasic expression pattern or are constitutively expressed [33]
In vivo studies demonstrated that higher BMP-2 retention times were more osteoconductive [71], and that prolonged BMP-2 delivery enhanced the protein’s osteogenic efficacy by comparison with a shorter-term delivery of an equivalent dose in a rat model [72]. Release should preferably be sustained over time, either in large single doses or in multiple smaller-dose applications. In evaluating the timing of the protein release, it is important to consider the dynamic nature of the healing zone, which depends on the type, location and appearance of the defect, the patients’ age and gender, their hormone and nutritional state, and any diseases, as well as other parameters influencing release rate, including the protein’s size and conformational changes, solubility, polymer/scaffold composition/geometry, and molecular weight [33].
Dose and concentration parameters are available for orthopedic clinical applications, where different anatomical sites require different therapeutic doses depending on the degree of vascularization, defect size and the number of resident responding cells. Supraphysiological dosages range from 0.01 mg/ml in small animal models (e.g. rats) to 0.4 mg/ml in rabbits, to more than 1.5 mg/ml in non-human primates [33].
Growth factor release from a delivery system may be diffusion-controlled, chemical or enzymatic reaction-controlled, solvent-controlled, or controlled by a combination of these mechanisms. Diffusion-controlled release is governed by the protein’s solubility and diffusion coefficient in the aqueous medium, protein partitioning between the aqueous medium and the material of the delivery system, protein loading and the diffusional distance. Chemical or enzymatic reaction-controlled systems include erodible systems, in which the protein is physically immobilized in the carrier matrix and released as the carrier undergoes degradation and dissolves. In solvent-controlled systems, the protein is embedded in a carrier matrix and a diffusional release occurs as a consequence of the rate-controlled penetration of the solvent (water) in the system [33].
Several GF delivery systems and carriers have been suggested for use in bone regeneration applications in an effort to find the optimal strategy for optimizing their clinical effectiveness and minimizing complications.
Delivery systems and carriers used for bone GFs should meet general requirements (Table 1) such as biocompatibility, predictable biodegradability, and the ability to provoke appropriate inflammatory responses. They must also have the following features: easy and cost-effective to manufacture; stability; easy handling and storage [33].
Biocompatibility | \n\t\t
Predictable biodegradability | \n\t\t
Low immunogenicity and antigenicity | \n\t\t
Enhancement of cellular vascularization and attachment | \n\t\t
Affinity with BMPs and bone | \n\t\t
Maintenance and enhancement of BMP bioactivity | \n\t\t
Malleability and ease of manufacture | \n\t\t
Safety, stability, sterility, availability and cost-effectiveness | \n\t\t
Regulatory agency approval for the clinical application of interest | \n\t\t
Controlled protein release at an effective dose for the appropriate period of time | \n\t\t
General requirements for BMP delivery systems
Carrier materials have been generally divided into four classes (Table 2): natural-origin polymers (collagen, hyaluronic acid, gelatin hydrogel complex, alginates and chitosan); inorganic materials (synthetic bone grafts, hydroxyapatite, calcium phosphates and bioactive glasses); synthetic biodegradable polymers (polylactic acid PLA, polyglycolide PLG, and their polymers PLGA, cholesterol-bearing pullulan nanogel CHPA), and composites (combinations of materials from the above different classes) [33].
To date, only BMP-2 and BMP-7 have been approved by the US Food and Drug Administration for human use in specific orthopedic applications, delivered using absorbable collagen sponges [33].
Class | \n\t\t\tTypes | \n\t\t\tAdvantages | \n\t\t\tDisadvantages | \n\t\t
Natural polymers | \n\t\t\tCollagen (gels, nano fibers, scaffolds and films) Fibrin glue Alginate and chitosan | \n\t\t\tBiocompatible, biodegradable, soluble in physiological fluids, natural affinity with BMPs | \n\t\t\tImmunogenicity (xenogenic), pathogen transmission, sensitivity to sterilization process | \n\t\t
Inorganic materials | \n\t\t\tSynthetic bone grafts CPC (calcium phosphate cement) Bioactive glasses, hydroxyapatite, hyaluronic acid, tricalcium phosphates, metal, ceramics and calcium sulfate | \n\t\t\tOsteoconductive, affinity with BMPs | \n\t\t\tBrittle, difficult mold, some formulations are exothermic | \n\t\t
Synthetic polymers | \n\t\t\tPLLA and PGLA and their copolymers CHPA | \n\t\t\tEasy to process and sterilize, flexible to tailor and reproducible, excellent chemical and mechanical properties | \n\t\t\tInflammatory response, localized pH drop and limited biological function | \n\t\t
Composites | \n\t\t\tCollagen-HA and titanium PLLA | \n\t\t\tDepending on the combination of the different materials’ characteristics | \n\t\t\tComplex to manufacture | \n\t\t
Major classes of carrier materials
Collagen is the protein most abundant in the connective tissue of mammals and the main non-mineral component of bone. It has been prepared in powders, membranes, films and implantable absorbable sponges, as well as in aqueous forms. Although it is versatile and easy to manipulate, the manufacture of collagen carriers is highly sensitive to several factors (including mass, soaking time, protein concentration, sterilization, buffer composition, pH and ionic strength) that directly affect rhBMPs binding [73]. Absorbable collagen sponges (ACS) have been evaluated in numerous in vivo models and clinical trials [6, 38,74-76]. In patients requiring staged maxillary sinus floor augmentation, rhBMP-2/ACS safely induced adequate bone formation for the purpose of placing and functionally loading endosseous dental implants [38]. The use of rhBMP-2/ACS without any concomitant bone grafting materials in critical-size mandibular defects prompted an excellent regeneration in a case review of 14 patients [75]. On the other hand, a recent study by Kao et al. demonstrated a more limited bone formation after a lateral-window sinus augmentation procedure involving rhBMP-2/ACS combined with Bio-Oss than when Bio-Oss was used alone [56].
Although they do away with the need to harvest autologous bone (with the associated pain), the use of animal-derived collagens is limited by their xenogenic nature: anti-type I collagen antibodies reportedly developed in almost 20% of patients treated with rhBMP-2/ACS [6]. In addition, collagen sponges are usually sterilized with ethylene oxide prior to soaking the sponge in the BMP solution, and this can affect the GF release kinetics or the protein’s bioactivity [73].
Alginate is a non-immunogenic polysaccharide used in a wide range of tissue engineering applications for its gel-forming properties. Alginate hydrogels allowing for a controlled, prolonged release of BMPs have only been studied in the preclinical phase, with promising results in vitro [72,77]
Chitosan is a cationic glucopolymer well known for its biological, chelating and adsorbing properties, and has been used as a BMP-2 carrier in a rat critical-size mandibular defect model, with positive results on histological and histomorphometric analysis [78].
Hyaluronic acid is a naturally-occurring biopolymer that plays a significant part in wound healing. It has been associated with an improved bone formation in mandibular defects by comparison with collagen sponges, when both were used to carry rhBMP-2 [79].
Hydroxyapatite (HAP) is well known for its osteoconductivity and has been widely used as a bone substitute material in clinical practice since the 1970s because of its ability to bond directly with bone [80]. Synthetic HAP comes in ceramic or non-ceramic, cementable forms, and has been evaluated as a scaffold and a controlled-release carrier, demonstrating lack of resorption and limited bone induction [6]. It has been combined with tri-calcium phosphates, collagen and other materials to form rigid, resorbable, porous carriers, in which case delivery and bone formation were generally found better than when HAP was used alone [81,82].
Unlike natural polymers and collagen, synthetic polymers pose no problem of immunogenicity or risk of disease transmission.
The most commonly-used polymers are polylactic acid (PLLA) and polyglycolic acid (PLGA). Bioresorbable PLLA/PLGA copolymers have been found superior to collagen when used to deliver rh BMP-2 to mandibular defects in the rat [83].
Bone grafts act as scaffolds for the ingrowth of vessels and bone-forming cells. During this osteoconductive bone regeneration process, the scaffold allows for bone to grow on its surface and inside the pores in the material. Given the biological limitations of other osteoconductive materials and the donor site morbidity after bone harvesting, the combination of osteoconductive scaffolds with osteoinductive proteins, such as BMPs, has been a major focus of research. [13,84]
Bone substitutes for use in dental and maxillofacial surgery are classified in three groups according to their origin. Allogenic bone grafts are derived from human donors, xenogenic bone grafts from other species (mostly bovine, but also equine, porcine and coralline), and the last group comprises the synthetically-produced materials. Synthetic bone grafts aim to imitate the natural bone’s structure. The most widely used are the calcium phosphates, including hydroxyapatite, tri-calcium phosphates (TCP) and composites of the two. By means of a thermal treatment (sintering) and subsequent cooling they can be transferred into ceramics with a very solid but porous structure and a rough surface closely resembling human bone.
Recent studies have reported successful bone regeneration after grafting on periodontal defects, using sinus floor elevation techniques, and in post-extraction socket defects using TCP carriers [58,65, 85].
Clinical studies reporting results of GFs delivery systems in oral surgery are revised in Table 3.
Some authors have also investigated the application of GFs to dental implant surfaces to stimulate local bone formation and osteointegration. In preclinical studies, functionalized titanium implant surfaces coated with rhBMP-2 have been shown to be able to stimulate bone formation around implants [35, 86]
References | \n\t\t\tStudy design | \n\t\t\tTotal number of patients | \n\t\t\tProtein | \n\t\t\tCarrier | \n\t\t\tApplication | \n\t\t\tMain findings | \n\t\t
Jung et al. 2003 [40] | \n\t\t\tRCT | \n\t\t\t11 | \n\t\t\trhBMP-2 | \n\t\t\tXenogenic bone (Bio-Oss) | \n\t\t\tMaxillary implant placement | \n\t\t\trhBMP-2 has the potential to predictably improve and accelerate guided bone regeneration therapy | \n\t\t
Boyne et al. 2005 [38] | \n\t\t\tRCT | \n\t\t\t48 | \n\t\t\trhBMP-2 | \n\t\t\tACS | \n\t\t\tMaxillary sinus floor elevation | \n\t\t\trhBMP-2/ACS safely induced adequate bone for the placement and functional loading of dental implants | \n\t\t
Herford and Boyne 2008 [75] | \n\t\t\tCase review | \n\t\t\t14 | \n\t\t\trhBMP-2 | \n\t\t\tACS | \n\t\t\tMandibular defect | \n\t\t\tBone formation could be identified radiographically after 5 to 6 months | \n\t\t
Van den Bergh et al. 2000 [76] | \n\t\t\t\n\t\t\t | 3 | \n\t\t\trhBMP-2 | \n\t\t\tType I collagen | \n\t\t\tMaxillary sinus floor elevation | \n\t\t\tPotential for initiating bone formation in the human maxillary sinus within 6 months after a sinus floor elevation, but its behavior is currently not sufficiently predictable in this application | \n\t\t
Kao et al., 2012 [56] | \n\t\t\tClinical trial | \n\t\t\t\n\t\t\t | rhBMP-2 | \n\t\t\tACS and xenogenic bone | \n\t\t\tSinus floor elevation | \n\t\t\tLess bone formed in patients treated with the rhBMP-2/ACS/xenogenic bone device | \n\t\t
Alonso et al. 2010 [89] | \n\t\t\tRCT | \n\t\t\t16 | \n\t\t\trhBMP-2 | \n\t\t\tCollagen | \n\t\t\tAlveolar defect closure in cleft lip and palate patients | \n\t\t\tSatisfactory bone healing at 6 months and reduced morbidity | \n\t\t
Stavropoulos et al. 2011 [63] | \n\t\t\tRCT | \n\t\t\t20 | \n\t\t\trhGDF-5 | \n\t\t\tβ-TCP | \n\t\t\tRegeneration of periodontal defects | \n\t\t\tGreater alveolar regeneration, differences not statistically significant | \n\t\t
Nevins et al. 2011 [49] | \n\t\t\tCohort study | \n\t\t\t\n\t\t\t | rhPDGF | \n\t\t\tMineral collagen scaffold | \n\t\t\tSocket preservation | \n\t\t\tNo statistically significant differences were observed | \n\t\t
Stavropoulos et al. 2011 [58] | \n\t\t\tRCT | \n\t\t\t31 | \n\t\t\trhGDF-5 | \n\t\t\tTCP | \n\t\t\tSinus floor elevation | \n\t\t\tComparable amount and similar quality of bone formation as in controls | \n\t\t
Jayakumar et al. 2011 [65] | \n\t\t\tRCT | \n\t\t\t54 | \n\t\t\trhPDGF | \n\t\t\tTCP | \n\t\t\tRegeneration of periodontal defects | \n\t\t\tIncreased bone formation and soft tissue healing | \n\t\t
McAllister et al. 2010 [85] | \n\t\t\tRCT | \n\t\t\t12 | \n\t\t\trhPDGF | \n\t\t\tβ-TCP | \n\t\t\tSocket preservation | \n\t\t\tSimilar histological findings at 3 months | \n\t\t
Triplett et al. 2009 [55] | \n\t\t\tRCT | \n\t\t\t160 | \n\t\t\trhBMP-2 | \n\t\t\tACS | \n\t\t\tSinus floor elevation | \n\t\t\tInduced bone was significantly denser, no marked differences in histological parameters. | \n\t\t
Clinical studies on GF delivery systems applicable in oral surgery
The potential applications of gene therapy have recently expanded to include the local treatment of bone defects. Gene transfer methods may circumvent many of the weaknesses of protein delivery to soft tissue wounds. The application of growth factors or soluble forms of cytokine receptors by means of gene transfer offers a greater sustainability than the use of a single protein application. Gene therapy may make growth factors more readily bio-available.
Gene transfer is accomplished by using viral and non-viral vectors. Examples of viral vectors are retroviruses, adenoviruses (Ads), and adeno-associated viruses (AAV), and non-viral vectors include plasmids and DNA polymer complexes.
Some authors have studied gene delivery via adenoviral or liposomal vectors carrying information for encoding recombinant human GFs combined with a collagen matrix in animal models [87,88].
The role of growth factors for alveolar bone regeneration in dentistry is a recent field of research, with a relative paucity of clinical studies. Findings seem to demonstrate a positive effect of GFs on intraoral hard and soft tissues healing, and the bone regeneration associated with implant therapy represents one of the main scenarios of interest. For the time being, however, the application of GFs in this field is limited by the dubious results, complications and side effects encountered so far. In particular, one of the main problems seems to be the relationship between the GF delivery and the timing of the healing process. Among the delivery systems tested to date, only collagen matrices have correlated with successful clinical results, albeit with some limitations. Other potential delivery systems have been studied only in a few animal models, and the currently available data are not enough for any final conclusions to be drawn. The development of dedicated and more “sophisticated” GF delivery systems is probably the most interesting area of research for the future.
Brachial plexus injuries are associated not only with motor and sensory functional impairment [1] but also with chronic pain in the affected upper limb [2, 3, 4, 5, 6, 7]. Most of these injuries are due to motor vehicle accidents, particularly motorbikes [1, 5], but a few of them can occur due to iatrogenia [8, 9, 10, 11, 12, 13, 14, 15, 16], particularly during lymph node biopsy [17, 18] or treatment of some malignancies [19].
\nThe pain is chronic [20], persistent [7], constant [21], burning [22] and throbbing [17], with paroxysmal discharges [3, 6, 23], particularly upon gentle rubbing the affected area [4].
\nThe pain is distributed in the distal areas of the upper limb, covering several dermatomes, mostly the caudal ones [24] and particularly the hand [5, 17, 23, 25]. The paroxysmal pain is felt in the arm [26]. Allodynia, hypersensitivity and electric-like discharges are present at the border between the normal and affected dermatomes [17, 26, 27, 28, 29], particularly between T1 and T2 at the posterior aspect of the elbow [26].
\nThe pain severity correlates with the magnitude of the brachial plexus injury [2, 3] and to the number of avulsed nerve roots [2, 3, 4, 21, 26, 30, 31, 32, 33], particularly when the lower roots are affected [24, 34, 35]. Nevertheless, Bertelli et al. [21] found that in isolated C8 and T1 nerve root avulsions, there was no pain at all.
\nThe pain does not appear immediately after the injury but a few days later [24] and no longer than 3 months after it [5, 6, 24, 26, 35, 36].
\nThe neuropathic pain can be associated with phantom [37] or stump pain [38] in case of upper limb amputation, or to complex regional pain syndrome (CRPS) [6], inducing a complex pain condition rather difficult to control [19, 30, 31].
\nSelf-mutilation has been described in 5–29% of obstetric brachial plexus injury cases [39, 40].
\nThe quality of life is seriously impaired with sleep disorders, family troubles, unemployment, chronic depression and social withdrawal [2, 5, 6, 17, 21, 41, 42, 43, 44]. Additionally, the chronic pain is a further hindrance to comply with a good rehabilitation programme, impairing a possible functional recovery [6, 45, 46]. Among all the disabilities induced by the brachial plexus injury, the pain has been found to be the symptom that most negatively affects the quality of life [47].
\nTreatment of this chronic pain can be troublesome, as the response to the different treatment modalities is poor and not all of them allow preservation of the remaining upper limb function [2, 5, 48].
\nAlthough 50–82.7% of brachial plexus injuries suffer from chronic pain [2, 3, 5, 6, 17, 35, 49, 50, 51], it is severe in 41% of them [32]. The incidence and severity are higher in nerve root avulsions [2, 3, 4, 7, 21, 30, 33], especially when all the roots are avulsed [2, 17, 21]. Overtime there is a spontaneous progressive improvement, so just after the injury 90% of patients suffer from pain but affects only 30% of them 3 years later [35, 36, 49].
\nPredisposing factors: the strongest is alcohol abuse [17], but smoking [6, 17], other coexistent pain conditions [6], like psychiatric co-morbidities [6, 17], using a sling [5] and the marital status (both married or divorced versus being single) also increase the pain incidence [5]. A longer time using a sling increases the chance of chronic pain because limb movement restriction has a negative impact on recovery [5].
\nBrachial plexus injuries may also be accompanied by partial or complete traumatic upper limb amputation. About 50–85% of these amputees will suffer from chronic pain [52, 53] particularly in more proximal amputations [53]. This pain usually starts 1 month postamputation [53], and in 54–87% of them, it is followed by phantom limb pain [37, 53, 54]. This kind of pain is felt also in extensive nerve root avulsions, particularly when all of them are affected [55].
\nCRPS is present in 21% of brachial plexus injuries [6], and once it starts it is usually lifelong unless treated [35].
\nThe neuropathic pain is induced by an injury to the somatosensory pathways [56, 57] like a brachial plexus injury, an upper limb amputation or both of them simultaneously [2, 7, 58].
\nThe peripheral nerve injury induces deafferentation [2] and damage to the C nerve fibres [59]. The dorsal horn neurons devoid of their peripheral sensorial input start to fire spontaneously and erratically [60, 61, 62, 63, 64], stimulating pain sensation in the higher central nervous system levels [65, 66]. In experimental studies it has been found that the spinal cord microglia and astrocytes are activated at the injury site [67] and help to maintain the neuropathic pain [68, 69, 70, 71, 72]. Higher levels like the thalamus and the motor cortex also undergo the same process by which deafferented neurons create new synapses and reorganize and start firing in abnormal patterns [7, 73, 74, 75, 76, 77]. Descending pathways modulate the neuropathic pain [78] creating new circuits that induce and maintain it [79, 80, 81]. The brain and spinal cord neuronal reorganization leads to an increased sensitivity to otherwise normal stimuli, lowering the threshold required to feel the sensation as pain and inducing secondary hyperalgesia and allodynia [4, 82]. It also explains why the pain often extends beyond the denervated area [26, 33] and why it manifests at the border areas between the partially denervated and normal dermatomes [17, 27].
\nAs mentioned above the pain seen after brachial plexus injury has two distinct patterns: paroxysmal and continuous. The first one is thought to originate from the deafferented posterior spinal horn neurons [60, 83], while the second one comes from the thalamus [74, 84]. In the phantom limb pain, the brain cortex undergoes a functional reorganization in response to the chronic pain [40, 85, 86].
\nSome have suggested that the neuropathic pain after brachial plexus avulsion is generated not by the avulsed nerve roots but by the remaining ones [67] that are also injured, although not so severely [34]. Although this might be true in some cases, it does not explain why the neuropathic pain severity is maximal when all nerve roots are avulsed [2, 17, 21, 55].
\nThis kind of pain, particularly in case of nerve root avulsions, is difficult to treat due to partial responses and frequent relapses [5, 6, 17]. The response to pharmacological treatments decreases when the pain intensity increases [6].
\nThe non-steroidal anti-inflammatory drugs (NSAIDs) are of little help in the chronic phase [17, 30].
\nThe first step is tricyclic antidepressants (TCAs) or serotonin and noradrenaline reuptake inhibitors [6, 57, 87]. Among TCAs, amitriptyline (25–125 mg/day) and venlafaxine (150–225 mg/day) are the most commonly used [6, 57]. They not only help with the pain but also with the accompanying nervous depression [57, 87]. A regular ECG surveillance is recommended as at high doses these drugs can induce cardiac arrhythmias [88]. Duloxetine, the most commonly used serotonin-noradrenaline reuptake inhibitor, is devoid of cholinergic or cardiac side effects [87].
\nThe second step is the combination of the above-mentioned drugs with anti-epileptic agents [89], like gabapentin or pregabalin [6, 19, 27, 57, 87]. Clonazepam at night time is very effective, but it can induce drowsiness, and some patients find it difficult to tolerate [90]. Other anti-epileptic drugs like topiramate, carbamazepine, oxcarbazepine and lamotrigine are also used but with limited success [57].
\nLidocaine (lignocaine) 5% patches applied to the painful area are the third line of medical treatment [27, 91, 92]. It controls the cold allodynia but not the mechanical one [73].
\nCapsaicin 8% patches are used but can cause severe local skin irritation [27].
\nOral cannabinoids, which were successful in controlling brachial plexus injury pain in rats [70], have limited success in humans and are not currently recommended [93].
\nOpioids (tramadol [6, 89], morphine, oxycodone and tapentadol) are to be avoided as they are not very effective in the treatment of neuropathic pain [32] and because of their addictive properties [27, 57, 91, 92]. In any case the opioid dose should never exceed 180 mg/day of oral morphine equivalents [57] and should be complemented with TCAs and anti-epileptic drugs [89].
\nOther drugs have been tried experimentally in rats, like rapamycin [94], intrathecal Trichostatin A (TSA) [94] or intravenous immunoglobulin [95], but there are no reports of their use in humans.
\nTranscutaneous electrical nerve stimulation (TENS) has been used to control and prevent the development of neuropathic pain after brachial plexus injury [35, 96, 97, 98]. Its main advantage is that it can be self-applied by the patient. However, it needs constant application, and at times it can provoke local skin irritation [35, 96, 97, 98].
\nThe common clinical features shared by neuropathic pain and CRPS hinder a pure clinical diagnosis [6]. Distinguishing between both of them is essential as the latter causes greater disabilities [99]. To differentiate them, an ultrasound examination can be performed, as the muscular architecture is preserved in neuropathic pain but not in CRPS [99].
\nMedical treatments can also classify the pain: stellate ganglion blocks will only relieve CRPS [6, 100, 101]. Other therapies for CRPS include botulinum toxin, which can be used to treat muscular trigger points [102] when found, and electroacupuncture, which has been found effective in controlling experimental brachial plexus pain in rats [103]. We have not found any publication reporting the use of electroacupuncture in human beings.
\nBrachial plexus injury repair by direct suture, by grafts or by nerve transfers, particularly sensory nerve transfers, minimizes the incidence and severity of neuropathic pain [4, 26, 34, 67, 104, 105, 106, 107, 108, 109], and the sooner the repair is done the better [25, 67]. CRPS is the exception as further surgery outside trapped nerve decompression seems to have a negative impact on the outcome [101]. In these cases either an interscalene [102] or stellate ganglion block [110] or a cervical spinal cord stimulator [111, 112, 113] is recommended instead. The phantom limb pain only improves with central nervous system procedures [114, 115].
\nThere are two main roads of action: neuromodulation and ablative procedures. The first group relies on applying electric impulses to different areas of the central or peripheral nervous system, aiming to block the transmission of the nerve impulses that are finally interpreted as pain in the sensory motor cortex. They are particularly effective for continuous pain but less so for paroxysmal painful discharges [84]. The ablative procedures aim to destroy the posterior horn spinal cord neurons that start to fire in an abnormal way after being disconnected from their peripheral sensory input [25, 64, 65, 66], controlling paroxysmal pain better than continuous pain [84].
\nPeripheral nerve stimulation provides 50–83% pain relief in 65–80% of the patients [116, 117, 118, 119, 120], and the affected limb preserves the residual function remaining after the injury [121]. Allodynia and neuropathic pain are controlled with mild improvement in the sensory function [116, 118]. The results are stable long-term [118, 119, 121]. The electrodes can be implanted with an open surgical procedure [117, 119] or percutaneously under ultrasound guidance [116, 120]. Unfortunately lead fracture, displacement or infection can spoil an initial successful result [116, 120]. A further refinement is to apply the stimulating electrodes not through a cuff around the affected nerve but by direct selective nerve fascicle stimulation [122]. In this way only the affected sensory fascicles are stimulated and not the motor ones, improving the results and reducing the side effects, particularly muscle spasms [122].
\nCervical spinal cord stimulation stops the transmission of the abnormal electrical impulses coming from the deafferented posterior spinal cord horn neurons [123], controlling the pain with preservation of the remaining upper limb function [112, 124, 125]. Its success rate in the treatment of neuropathic pain associated with brachial plexus injuries is 50% [51, 111, 112, 113, 124, 125, 126, 127, 128, 129]. It is particularly useful in CRPS [112] but it also helpful in nerve root avulsions [129]. In cases of failed previous dorsal root entry zone (DREZ), lesioning can provide good pain control [113]. Contrariwise, when the spinal cord stimulation failed the DREZ-otomy through radiofrequency, it yields suboptimal results [130]. Nevertheless several research groups recommend to restrict the cervical spinal cord stimulation for failed previous DREZ-otomy due to its high economical costs [25, 131, 132, 133]. A trial period is needed before the definitive pulse generator implantation to predict the results [129]. The stimulation parameters can be modified according to the patient’s individual needs through an external programming device. The electrodes can be implanted percutaneously or surgically. Lead fracture or dislocation and battery exhaustion will require surgical revision of the system. Some patients experience discomfort due to paresthesias particularly when rotating the head [111, 124]. This can be minimized by reprograming the active electrodes and the intensity of the electrical stimuli.
\nPulsed radiofrequency has been reported in a few cases of brachial plexus injury including one with concomitant limb amputation, with a 60–70% pain improvement in a 6-month follow-up [38, 134]. The main advantage is that radiofrequency does not induce additional motor or sensory deficit, although the results are not long-lasting [135]. The data are insufficient to draw any definitive conclusions [38, 134, 135].
\nIn small clinical series of patients, deep brain stimulation has shown a 55% improvement in neuropathic pain arising from brachial plexus injury and traumatic amputation pain [20, 58, 136]. After 1 year the effectivity is reduced in many patients, and increasing the intensity of the electrical stimuli is not always successful to improve the deteriorating results [20]. There is no agreement on where is the best target for the stimulation: some recommend the sensory thalamus [20, 58] and others the periaqueductal grey matter [137, 138].
\nIn neuropathic pain induced by brachial plexus injury, motor cortex stimulation has shown a 42% effectiveness in controlling the continuous pain but no effectiveness for the paroxysmal discharges [84, 139]. A major drawback is the lack of factors to be able to predict the results to be expected [84]. This is particularly important considering the high cost and surgical risks involved in this technology.
\nThe medial thalamotomy, the spinothalamic tractotomy, and the anterolateral tractotomy have been abandoned due to the limited pain control they provide and the side effects they carry [119].
\nThe DREZ is an anatomical area of the spinal cord composed by the dorsal rootlets, Lissauer’s tract and the dorsal horn [25]. DREZ-otomy aims to destroy the neurons located in the posterior horn of the spinal cord that start firing abnormally once deprived of their peripheral sensory input [25, 140]. It has proved particularly effective in the control of brachial plexus-induced neuropathic pain [22, 23, 28, 48, 140, 141], but it is a destructive procedure that can be applied when no residual upper limb function has to be preserved (i.e. nerve root avulsions). It is particularly effective in controlling the paroxysmal pain but not so much in the constant aspect of it [23, 24, 25, 84, 133, 139, 142]. It provides a better pain control than the neuromodulation procedures, with a reported long-term success rates of 50–75% [22, 25, 29, 48, 143]. Unfortunately about 10% of patients develop ipsilateral leg weakness and ataxia [22, 23, 24, 28, 48, 133, 140, 141] due to the vicinity of the area to be lesioned to the motor corticospinal tract laterally and the dorsal column with proprioceptive information medially [25, 140]. This successful pain control correlates with an improvement in anxiety and depression and in a third of patients in returning to work [133, 144]. The pain improvement with this technique is independent of the time elapsed since the injury and the DREZ-otomy [25, 133]. Pain recurrence is expected in 13–20% of the patients [22, 23, 25, 28, 29, 132, 143, 145, 146, 147] particularly in those with constant type of pain [23, 24, 139] but with an acceptable pain control in over 60% of them [132, 143]. The recurrences seem to be more common in the first 12 months post-op and much rarer after 5 years of follow-up [48, 132]. Pain control and recurrences seem to be less common among nerve root avulsions than with other more peripheral brachial plexus injuries [143, 145]. Some surgeons have considered that a bad result would mean a DREZ lesion of insufficient size [25, 131] and used the intraoperative ultrasound imaging to guide the shape and size of those lesions [131]. They reported an initial 100% pain control that decreased to 87% on 47.5 months follow-up but at the price of a higher rate of lower extremity weakness and ataxia [131] (17%, compared to 10% in other patient series [22, 23, 24, 28, 48, 140, 141]). These results also reflect that apart from the spinal cord, there are other higher central nervous system areas involved in the generation and maintenance of the neuropathic pain induced after brachial plexus injury [148].
\nLack of DREZ region damage confirmed in preoperative MRI seems to be an indicator of successful pain control with the DREZ procedure to the point that no patient with spinal cord dorsal horn abnormalities had a completely pain-free outcome [22]. It is suggested that if the posterior horn is abnormal, the thalamus will most likely develop deafferented neurons that will start firing in an abnormal pattern and thus the treatment should be directed there and not to the spinal cord [22]. This observation contradicts the fact that surgically amputated patients due to different medical conditions in whom a normal spinal cord anatomy is preserved fare worse with the DREZ operation than those that had a traumatic amputation [115]. In these DREZ-otomy failed cases, a cervical spinal cord stimulator is recommended [113]. Post-operative MRI examinations in radiofrequency DREZ lesions have shown that the surgically lesioned area extends beyond the posterior horn [149]. This is in concordance with the clinical fact that some patients develop post-operative leg weakness, ataxia and sensory abnormalities below the operated area [22, 23, 24, 28, 48, 133, 140, 141].
\nDREZ-otomy provides 83% pain control rate in phantom pain [115, 150, 151], 67% in burning pain and 29% for stump pain [115, 152]. Both amputation and nerve root avulsion phantom pain seem to benefit from DREZ-otomies [115, 150, 151]. The results in pain improvement are better in traumatic amputations than in those due to medical conditions [28, 115]. Some researchers recommend to start with neurostimulation in phantom limb pain and to recourse to the DREZ-otomy as a last resort [152].
\nThe DREZ-otomy can be created microsurgicaly (Sindou’s technique) [25], with radiofrequency (Nashold’s technique) [29, 48], with laser [153, 154, 155, 156] or even with an ultrasonic microprobe [131], but there are no major differences in pain control or patients’ quality of life between them [142, 156]. The microsurgical technique is performed with the regular bipolar forceps, which is less expensive than the other options (radiofrequency, laser, ultrasonic probe), making it ideal for countries with limited resources [144, 157]. Some scientists have attempted intraoperative neurophysiological monitoring to improve the clinical results [65, 158, 159]. Freeing the spinal cord completely helps to stop pain induction with neck movements [25]. A concern that has not yet been studied in detail is the possible long-term effects of extensive cervical laminectomies required for the procedure, as it might accelerate cervical kyphotic deformity with cervical spinal cord myelopathy [147]. In any case the original full bilateral cervical C5-T1 laminectomies [25, 140] have been replaced in many surgical units by hemi-laminectomies.
\nBrachial plexus injuries can be the source of chronic pain. This pain can be neuropathic, CRPS and/or phantom limb, particularly if there is extensive nerve root avulsion or an upper limb amputation. The pain is oftentimes excruciating and leads to a bad quality of life even interfering with the physiotherapy needed to achieve a good recovery. The response to treatment of this pain is not always as successful as expected. Some patients respond to medication, but many need neuromodulation or ablative procedures. The most effective surgical technique is the DREZ-otomy, but 10% of patients develop side effects. If the ablative procedures fail, cervical spinal cord stimulation can be attempted.
\nYou have been successfully unsubscribed.
",metaTitle:"Unsubscribe Successful",metaDescription:"You have been successfully unsubscribed.",metaKeywords:null,canonicalURL:"/page/unsubscribe-successful",contentRaw:'[{"type":"htmlEditorComponent","content":""}]'},components:[{type:"htmlEditorComponent",content:""}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5717},{group:"region",caption:"Middle and South America",value:2,count:5179},{group:"region",caption:"Africa",value:3,count:1696},{group:"region",caption:"Asia",value:4,count:10260},{group:"region",caption:"Australia and Oceania",value:5,count:890},{group:"region",caption:"Europe",value:6,count:15670}],offset:12,limit:12,total:117458},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateendthirdsteppublish"},books:[],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:11},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:14},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:7},{group:"topic",caption:"Computer and Information Science",value:9,count:10},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:4},{group:"topic",caption:"Engineering",value:11,count:16},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:51},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:5},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:0,limit:12,total:null},popularBooks:{featuredBooks:[],offset:0,limit:12,total:null},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"6934",title:"Psycho-Social Aspects of Human Sexuality and Ethics",subtitle:null,isOpenForSubmission:!1,hash:"44731b106aa0d1ab5c64a7394483c7d5",slug:"psycho-social-aspects-of-human-sexuality-and-ethics",bookSignature:"Dhastagir Sultan Sheriff",coverURL:"https://cdn.intechopen.com/books/images_new/6934.jpg",editedByType:"Edited by",editors:[{id:"167875",title:"Dr.",name:"Dhastagir Sultan",middleName:null,surname:"Sheriff",slug:"dhastagir-sultan-sheriff",fullName:"Dhastagir Sultan Sheriff"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10062",title:"Forecasting in Mathematics",subtitle:"Recent Advances, New Perspectives and Applications",isOpenForSubmission:!1,hash:"9a3ad05fef0502040d2a238ad22487c0",slug:"forecasting-in-mathematics-recent-advances-new-perspectives-and-applications",bookSignature:"Abdo Abou Jaoude",coverURL:"https://cdn.intechopen.com/books/images_new/10062.jpg",editedByType:"Edited by",editors:[{id:"248271",title:"Dr.",name:"Abdo",middleName:null,surname:"Abou Jaoude",slug:"abdo-abou-jaoude",fullName:"Abdo Abou Jaoude"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9043",title:"Parenting",subtitle:"Studies by an Ecocultural and Transactional Perspective",isOpenForSubmission:!1,hash:"6d21066c7438e459e4c6fb13217a5c8c",slug:"parenting-studies-by-an-ecocultural-and-transactional-perspective",bookSignature:"Loredana Benedetto and Massimo Ingrassia",coverURL:"https://cdn.intechopen.com/books/images_new/9043.jpg",editedByType:"Edited by",editors:[{id:"193200",title:"Prof.",name:"Loredana",middleName:null,surname:"Benedetto",slug:"loredana-benedetto",fullName:"Loredana Benedetto"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10075",title:"Nonlinear Optics",subtitle:"From Solitons to Similaritons",isOpenForSubmission:!1,hash:"b034b2a060292c8511359aec0db1002c",slug:"nonlinear-optics-from-solitons-to-similaritons",bookSignature:"İlkay Bakırtaş and Nalan Antar",coverURL:"https://cdn.intechopen.com/books/images_new/10075.jpg",editedByType:"Edited by",editors:[{id:"186388",title:"Prof.",name:"İlkay",middleName:null,surname:"Bakırtaş",slug:"ilkay-bakirtas",fullName:"İlkay Bakırtaş"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10116",title:"Nano- and Microencapsulation",subtitle:"Techniques and Applications",isOpenForSubmission:!1,hash:"8d92c5999718734b36a0cc3a6af7c7f6",slug:"nano-and-microencapsulation-techniques-and-applications",bookSignature:"Nedal Abu-Thabit",coverURL:"https://cdn.intechopen.com/books/images_new/10116.jpg",editedByType:"Edited by",editors:[{id:"308436",title:"Associate Prof.",name:"Nedal",middleName:null,surname:"Abu-Thabit",slug:"nedal-abu-thabit",fullName:"Nedal Abu-Thabit"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9881",title:"Perovskite and Piezoelectric Materials",subtitle:null,isOpenForSubmission:!1,hash:"8fa0e0f48567bbc50fbb3bfdde6f9a0b",slug:"perovskite-and-piezoelectric-materials",bookSignature:"Someshwar Pola, Neeraj Panwar and Indrani Coondoo",coverURL:"https://cdn.intechopen.com/books/images_new/9881.jpg",editedByType:"Edited by",editors:[{id:"177037",title:"Dr.",name:"Someshwar",middleName:null,surname:"Pola",slug:"someshwar-pola",fullName:"Someshwar Pola"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9394",title:"Genotoxicity and Mutagenicity",subtitle:"Mechanisms and Test Methods",isOpenForSubmission:!1,hash:"9ee7e597358dbbfb5e33d0beb76e6fff",slug:"genotoxicity-and-mutagenicity-mechanisms-and-test-methods",bookSignature:"Sonia Soloneski and Marcelo L. Larramendy",coverURL:"https://cdn.intechopen.com/books/images_new/9394.jpg",editedByType:"Edited by",editors:[{id:"14863",title:"Dr.",name:"Sonia",middleName:null,surname:"Soloneski",slug:"sonia-soloneski",fullName:"Sonia Soloneski"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editedByType:"Edited by",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editedByType:"Edited by",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9569",title:"Methods in Molecular Medicine",subtitle:null,isOpenForSubmission:!1,hash:"691d3f3c4ac25a8093414e9b270d2843",slug:"methods-in-molecular-medicine",bookSignature:"Yusuf Tutar",coverURL:"https://cdn.intechopen.com/books/images_new/9569.jpg",editedByType:"Edited by",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"200",title:"Public Health",slug:"medicine-public-health",parent:{title:"Medicine",slug:"medicine"},numberOfBooks:70,numberOfAuthorsAndEditors:1681,numberOfWosCitations:851,numberOfCrossrefCitations:670,numberOfDimensionsCitations:1695,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"medicine-public-health",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editedByType:"Edited by",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9047",title:"Nursing",subtitle:"New Perspectives",isOpenForSubmission:!1,hash:"1500bf539d1400c51b941e95f3a1f0f9",slug:"nursing-new-perspectives",bookSignature:"Serpil Çelik Durmuş",coverURL:"https://cdn.intechopen.com/books/images_new/9047.jpg",editedByType:"Edited by",editors:[{id:"189558",title:"Ph.D.",name:"Serpil",middleName:null,surname:"Çelik Durmuş",slug:"serpil-celik-durmus",fullName:"Serpil Çelik Durmuş"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6951",title:"Personalized Medicine, in Relation to Redox State, Diet and Lifestyle",subtitle:null,isOpenForSubmission:!1,hash:"2940f812b4520a28d958f5c23c606f02",slug:"personalized-medicine-in-relation-to-redox-state-diet-and-lifestyle",bookSignature:"Faik Atroshi",coverURL:"https://cdn.intechopen.com/books/images_new/6951.jpg",editedByType:"Edited by",editors:[{id:"65639",title:"Dr.",name:"Faik",middleName:null,surname:"Atroshi",slug:"faik-atroshi",fullName:"Faik Atroshi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"3",chapterContentType:"chapter",authoredCaption:"Authored by"}},{type:"book",id:"8467",title:"Accident Analysis and Prevention",subtitle:null,isOpenForSubmission:!1,hash:"81f08fa6308d78fe644f8544321511cf",slug:"accident-analysis-and-prevention",bookSignature:"Murat Darçın",coverURL:"https://cdn.intechopen.com/books/images_new/8467.jpg",editedByType:"Edited by",editors:[{id:"196869",title:"Dr.",name:"Murat",middleName:null,surname:"Darçın",slug:"murat-darcin",fullName:"Murat Darçın"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8270",title:"Maternal and Child Health Matters Around the World",subtitle:null,isOpenForSubmission:!1,hash:"970e2fb7930d29a8d805900b86da459f",slug:"maternal-and-child-health-matters-around-the-world",bookSignature:"Masoud Mohammadnezhad and Nafisa Huq",coverURL:"https://cdn.intechopen.com/books/images_new/8270.jpg",editedByType:"Edited by",editors:[{id:"257189",title:"Dr.",name:"Masoud",middleName:null,surname:"Mohammadnezhad",slug:"masoud-mohammadnezhad",fullName:"Masoud Mohammadnezhad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9138",title:"Public Health in Developing Countries",subtitle:"Challenges and Opportunities",isOpenForSubmission:!1,hash:"28c7e86f71905feb65668941c4f259f4",slug:"public-health-in-developing-countries-challenges-and-opportunities",bookSignature:"Edlyne Eze Anugwom and Niyi Awofeso",coverURL:"https://cdn.intechopen.com/books/images_new/9138.jpg",editedByType:"Edited by",editors:[{id:"293469",title:null,name:"Edlyne Eze",middleName:null,surname:"Anugwom",slug:"edlyne-eze-anugwom",fullName:"Edlyne Eze Anugwom"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8831",title:"Environmental Factors Affecting Human Health",subtitle:null,isOpenForSubmission:!1,hash:"88c049685e3808385ac61471dd7f4fbf",slug:"environmental-factors-affecting-human-health",bookSignature:"Ivan Uher",coverURL:"https://cdn.intechopen.com/books/images_new/8831.jpg",editedByType:"Edited by",editors:[{id:"227237",title:"Prof.",name:"Ivan",middleName:null,surname:"Uher",slug:"ivan-uher",fullName:"Ivan Uher"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9105",title:"Heavy Metal Toxicity in Public Health",subtitle:null,isOpenForSubmission:!1,hash:"a2e4f3c444775950ab18bce58a754777",slug:"heavy-metal-toxicity-in-public-health",bookSignature:"John Kanayochukwu Nduka and Mohamed Nageeb Rashed",coverURL:"https://cdn.intechopen.com/books/images_new/9105.jpg",editedByType:"Edited by",editors:[{id:"107866",title:"Dr.",name:"John Kanayochukwu",middleName:null,surname:"Nduka",slug:"john-kanayochukwu-nduka",fullName:"John Kanayochukwu Nduka"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7620",title:"Safety and Health for Workers",subtitle:"Research and Practical Perspective",isOpenForSubmission:!1,hash:"1233909d682e2cced428e1042fd40ad4",slug:"safety-and-health-for-workers-research-and-practical-perspective",bookSignature:"Bankole Fasanya",coverURL:"https://cdn.intechopen.com/books/images_new/7620.jpg",editedByType:"Edited by",editors:[{id:"214494",title:"Dr.",name:"Bankole",middleName:"Kolawole",surname:"Fasanya",slug:"bankole-fasanya",fullName:"Bankole Fasanya"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8036",title:"Healthcare Access",subtitle:"Regional Overviews",isOpenForSubmission:!1,hash:"84f870b3d688da8dd09779ef7507b850",slug:"healthcare-access-regional-overviews",bookSignature:"Umar Bacha, Urška Rozman and Sonja Šostar Turk",coverURL:"https://cdn.intechopen.com/books/images_new/8036.jpg",editedByType:"Edited by",editors:[{id:"244265",title:"Dr.",name:"Umar",middleName:null,surname:"Bacha",slug:"umar-bacha",fullName:"Umar Bacha"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7856",title:"Nutrition and HIV/AIDS",subtitle:"Implication for Treatment, Prevention and Cure",isOpenForSubmission:!1,hash:"94229224705db9f1cd430a32aa777bef",slug:"nutrition-and-hiv-aids-implication-for-treatment-prevention-and-cure",bookSignature:"Nancy Dumais",coverURL:"https://cdn.intechopen.com/books/images_new/7856.jpg",editedByType:"Edited by",editors:[{id:"40783",title:"Dr.",name:"Nancy",middleName:null,surname:"Dumais",slug:"nancy-dumais",fullName:"Nancy Dumais"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8607",title:"Evaluation of Health Services",subtitle:null,isOpenForSubmission:!1,hash:"dbea1d7a6cd5428a713f35c234f5583b",slug:"evaluation-of-health-services",bookSignature:"Sandeep Reddy and Aida Isabel Tavares",coverURL:"https://cdn.intechopen.com/books/images_new/8607.jpg",editedByType:"Edited by",editors:[{id:"230704",title:"Associate Prof.",name:"Sandeep",middleName:null,surname:"Reddy",slug:"sandeep-reddy",fullName:"Sandeep Reddy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:70,mostCitedChapters:[{id:"27687",doi:"10.5772/29869",title:"Heavy Metals and Human Health",slug:"heavy-metals-and-human-health",totalDownloads:18248,totalCrossrefCites:52,totalDimensionsCites:106,book:{slug:"environmental-health-emerging-issues-and-practice",title:"Environmental Health",fullTitle:"Environmental Health - Emerging Issues and Practice"},signatures:"Simone Morais, Fernando Garcia e Costa and Maria de Lourdes Pereira",authors:[{id:"13875",title:"Prof.",name:"Simone",middleName:null,surname:"Morais",slug:"simone-morais",fullName:"Simone Morais"},{id:"79715",title:"Prof.",name:"Maria De Lourdes",middleName:null,surname:"Pereira",slug:"maria-de-lourdes-pereira",fullName:"Maria De Lourdes Pereira"},{id:"87294",title:"Prof.",name:"Fernando",middleName:null,surname:"Garcia E Costa",slug:"fernando-garcia-e-costa",fullName:"Fernando Garcia E Costa"}]},{id:"36935",doi:"10.5772/37886",title:"Gender Differences in Food Choice and Dietary Intake in Modern Western Societies",slug:"gender-differences-in-food-choice-and-dietary-intake-in-modern-western-societies",totalDownloads:17179,totalCrossrefCites:32,totalDimensionsCites:87,book:{slug:"public-health-social-and-behavioral-health",title:"Public Health",fullTitle:"Public Health - Social and Behavioral Health"},signatures:"Claudia Arganini, Anna Saba, Raffaella Comitato, Fabio Virgili and Aida Turrini",authors:[{id:"114665",title:"Dr.",name:"Aida",middleName:null,surname:"Turrini",slug:"aida-turrini",fullName:"Aida Turrini"},{id:"116008",title:"Dr.",name:"Claudia",middleName:null,surname:"Arganini",slug:"claudia-arganini",fullName:"Claudia Arganini"},{id:"116171",title:"MSc.",name:"Anna",middleName:null,surname:"Saba",slug:"anna-saba",fullName:"Anna Saba"},{id:"116173",title:"Dr.",name:"Fabio",middleName:null,surname:"Virgili",slug:"fabio-virgili",fullName:"Fabio Virgili"},{id:"116174",title:"Dr.",name:"Raffaella",middleName:null,surname:"Comitato",slug:"raffaella-comitato",fullName:"Raffaella Comitato"}]},{id:"29979",doi:"10.5772/25344",title:"The Therapeutic Benefits of Essential Oils",slug:"the-therapeutic-benefits-of-essential-oils",totalDownloads:23334,totalCrossrefCites:31,totalDimensionsCites:83,book:{slug:"nutrition-well-being-and-health",title:"Nutrition, Well-Being and Health",fullTitle:"Nutrition, Well-Being and Health"},signatures:"Abdelouaheb Djilani and Amadou Dicko",authors:[{id:"63044",title:"Prof.",name:"Jilani",middleName:null,surname:"AbdelWahab",slug:"jilani-abdelwahab",fullName:"Jilani AbdelWahab"},{id:"116762",title:"Prof.",name:"Amadou",middleName:null,surname:"Dicko",slug:"amadou-dicko",fullName:"Amadou Dicko"}]}],mostDownloadedChaptersLast30Days:[{id:"56223",title:"Volunteering in Palliative Care in France: “A Tough Job”; Patient, Family, Caregiver, and Volunteer Perspectives",slug:"volunteering-in-palliative-care-in-france-a-tough-job-patient-family-caregiver-and-volunteer-perspec",totalDownloads:2366,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"highlights-on-several-underestimated-topics-in-palliative-care",title:"Highlights on Several Underestimated Topics in Palliative Care",fullTitle:"Highlights on Several Underestimated Topics in Palliative Care"},signatures:"Yaël Tibi-Lévy and Martine Bungener",authors:[{id:"88839",title:"Dr.",name:"Martine",middleName:null,surname:"Bungener",slug:"martine-bungener",fullName:"Martine Bungener"},{id:"205065",title:"Ph.D.",name:"Yaël",middleName:null,surname:"Tibi-Levy",slug:"yael-tibi-levy",fullName:"Yaël Tibi-Levy"}]},{id:"58916",title:"Factors Affecting the Attitudes of Women toward Family Planning",slug:"factors-affecting-the-attitudes-of-women-toward-family-planning",totalDownloads:5683,totalCrossrefCites:2,totalDimensionsCites:6,book:{slug:"family-planning",title:"Family Planning",fullTitle:"Family Planning"},signatures:"Nazli Sensoy, Yasemin Korkut, Selcuk Akturan, Mehmet Yilmaz,\nCanan Tuz and Bilge Tuncel",authors:[{id:"216377",title:"Prof.",name:"Nazli",middleName:null,surname:"Sensoy",slug:"nazli-sensoy",fullName:"Nazli Sensoy"},{id:"216589",title:"Dr.",name:"Yasemin",middleName:null,surname:"Korkut",slug:"yasemin-korkut",fullName:"Yasemin Korkut"},{id:"216595",title:"Dr.",name:"Selcuk",middleName:null,surname:"Akturan",slug:"selcuk-akturan",fullName:"Selcuk Akturan"},{id:"216596",title:"Dr.",name:"Canan",middleName:null,surname:"Tuz",slug:"canan-tuz",fullName:"Canan Tuz"},{id:"216598",title:"Dr.",name:"Bilge",middleName:null,surname:"Tuncel",slug:"bilge-tuncel",fullName:"Bilge Tuncel"},{id:"216599",title:"Dr.",name:"Mehmet",middleName:null,surname:"Yilmaz",slug:"mehmet-yilmaz",fullName:"Mehmet Yilmaz"}]},{id:"44569",title:"Health Care Waste Management – Public Health Benefits, and the Need for Effective Environmental Regulatory Surveillance in Federal Republic of Nigeria",slug:"health-care-waste-management-public-health-benefits-and-the-need-for-effective-environmental-regulat",totalDownloads:7272,totalCrossrefCites:4,totalDimensionsCites:12,book:{slug:"current-topics-in-public-health",title:"Current Topics in Public Health",fullTitle:"Current Topics in Public Health"},signatures:"Nkechi Chuks Nwachukwu, Frank Anayo Orji and Ositadinma\nChinyere Ugbogu",authors:[{id:"85404",title:"Dr.",name:"Nkechi Chuks",middleName:null,surname:"Nwachukwu",slug:"nkechi-chuks-nwachukwu",fullName:"Nkechi Chuks Nwachukwu"},{id:"120194",title:"Dr.",name:"Orji",middleName:null,surname:"Frank Anayo",slug:"orji-frank-anayo",fullName:"Orji Frank Anayo"},{id:"161783",title:"Dr.",name:"Ositadinma Chinyere",middleName:null,surname:"Ugbogu",slug:"ositadinma-chinyere-ugbogu",fullName:"Ositadinma Chinyere Ugbogu"}]},{id:"56224",title:"Diet Quality Indices for Nutrition Assessment: Types and Applications",slug:"diet-quality-indices-for-nutrition-assessment-types-and-applications",totalDownloads:3618,totalCrossrefCites:1,totalDimensionsCites:4,book:{slug:"functional-food-improve-health-through-adequate-food",title:"Functional Food",fullTitle:"Functional Food - Improve Health through Adequate Food"},signatures:"Maria Luisa Poyatos Guerrero and Fernando Pérez-Rodríguez",authors:[{id:"82252",title:"Dr.",name:"Fernando",middleName:null,surname:"Pérez-Rodríguez",slug:"fernando-perez-rodriguez",fullName:"Fernando Pérez-Rodríguez"},{id:"207713",title:"MSc.",name:"Maria Luisa",middleName:null,surname:"Poyatos-Guerrero",slug:"maria-luisa-poyatos-guerrero",fullName:"Maria Luisa Poyatos-Guerrero"}]},{id:"55808",title:"The Role of Legumes in Human Nutrition",slug:"the-role-of-legumes-in-human-nutrition",totalDownloads:3763,totalCrossrefCites:19,totalDimensionsCites:37,book:{slug:"functional-food-improve-health-through-adequate-food",title:"Functional Food",fullTitle:"Functional Food - Improve Health through Adequate Food"},signatures:"Yvonne Maphosa and Victoria A. Jideani",authors:[{id:"201151",title:"Ph.D. Student",name:"Yvonne",middleName:null,surname:"Maphosa",slug:"yvonne-maphosa",fullName:"Yvonne Maphosa"}]},{id:"64294",title:"Evaluation of Effectiveness of Peer Education on Smoking Behaviour",slug:"evaluation-of-effectiveness-of-peer-education-on-smoking-behaviour",totalDownloads:622,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"smoking-prevention-and-cessation",title:"Smoking Prevention and Cessation",fullTitle:"Smoking Prevention and Cessation"},signatures:"Nurcan Bilgiç and Türkan Günay",authors:[{id:"228458",title:"Dr.",name:"Nurcan",middleName:null,surname:"Bilgiç",slug:"nurcan-bilgic",fullName:"Nurcan Bilgiç"},{id:"270102",title:"Prof.",name:"Türkan",middleName:null,surname:"Günay",slug:"turkan-gunay",fullName:"Türkan Günay"}]},{id:"29979",title:"The Therapeutic Benefits of Essential Oils",slug:"the-therapeutic-benefits-of-essential-oils",totalDownloads:23334,totalCrossrefCites:31,totalDimensionsCites:83,book:{slug:"nutrition-well-being-and-health",title:"Nutrition, Well-Being and Health",fullTitle:"Nutrition, Well-Being and Health"},signatures:"Abdelouaheb Djilani and Amadou Dicko",authors:[{id:"63044",title:"Prof.",name:"Jilani",middleName:null,surname:"AbdelWahab",slug:"jilani-abdelwahab",fullName:"Jilani AbdelWahab"},{id:"116762",title:"Prof.",name:"Amadou",middleName:null,surname:"Dicko",slug:"amadou-dicko",fullName:"Amadou Dicko"}]},{id:"62561",title:"Preventing Vaccine Failure in Poultry Flocks",slug:"preventing-vaccine-failure-in-poultry-flocks",totalDownloads:2672,totalCrossrefCites:1,totalDimensionsCites:4,book:{slug:"immunization-vaccine-adjuvant-delivery-system-and-strategies",title:"Immunization",fullTitle:"Immunization - Vaccine Adjuvant Delivery System and Strategies"},signatures:"Aamir Sharif and Tanveer Ahmad",authors:[{id:"246237",title:"Dr.",name:"Aamir",middleName:null,surname:"Sharif",slug:"aamir-sharif",fullName:"Aamir Sharif"},{id:"259271",title:"Dr.",name:"Tanveer",middleName:null,surname:"Ahmad",slug:"tanveer-ahmad",fullName:"Tanveer Ahmad"}]},{id:"66183",title:"Introductory Chapter: Bio-Psychosocial Model of Health",slug:"introductory-chapter-bio-psychosocial-model-of-health",totalDownloads:1642,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"psychology-of-health-biopsychosocial-approach",title:"Psychology of Health",fullTitle:"Psychology of Health - Biopsychosocial Approach"},signatures:"Simon George Taukeni",authors:[{id:"202046",title:"Dr.",name:"Simon George",middleName:null,surname:"Taukeni",slug:"simon-george-taukeni",fullName:"Simon George Taukeni"}]},{id:"69876",title:"Leadership Styles in Nursing",slug:"leadership-styles-in-nursing",totalDownloads:512,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"nursing-new-perspectives",title:"Nursing",fullTitle:"Nursing - New Perspectives"},signatures:"Serpil Çelik Durmuş and Kamile Kırca",authors:null}],onlineFirstChaptersFilter:{topicSlug:"medicine-public-health",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/238144/jorge-guimaraes",hash:"",query:{},params:{id:"238144",slug:"jorge-guimaraes"},fullPath:"/profiles/238144/jorge-guimaraes",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()